stop O
bleeding B-NEG
and O
relieve O
pain B-NEG

-DOCSTART- O

clear O
( O
pathogenic O
) O
fire B-NEU
and O
invigorate O
blood B-DNP

-DOCSTART- O

To O
lessen O
contracture B-NEG
, O
regulate O
stomach B-NEU
function I-NEU
, O
and O
dispel O
contracture B-NEG
. O

-DOCSTART- O

frequent O
vomiting B-NEG

-DOCSTART- O

To O
dispel O
phlegm B-NEG
, O
to O
restore O
consciousness B-NEU
, O
and O
to O
reduce O
modulation B-NEU
and O
cause O
the O
subsidence B-NEU
of I-NEU
swelling I-NEU
. O

-DOCSTART- O

sore B-NEG

-DOCSTART- O

unblock O
the O
network B-DNP
vessels I-DNP

-DOCSTART- O

deficiency B-NEG
of I-NEG
the I-NEG
kidney I-NEG
; O

deficiency B-NEG
syndrome I-NEG
of I-NEG
the I-NEG
kidney I-NEG
the O
pathological B-NEG
changes I-NEG
due O
to O
deficiency B-NEG
of I-NEG
the I-NEG
kidney I-NEG
essence I-NEG
, O
usually O
characterized O
by O
dizziness B-NEG
, O
tinnitus B-NEG
, O
lumbago B-NEG
, O
nocturnal B-NEU
emission I-NEU
, O
impotence B-NEG
, O
lassitude B-NEG
, O
forgetfulness B-NEG
. O

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
Body B-NEU
weight I-NEU
regulation I-NEU
, O
Improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU

-DOCSTART- O

Bacterial B-NEG
infections I-NEG
of O
the O
eyes O
. O

-DOCSTART- O

moisten O
skin O

-DOCSTART- O

cosolidate O
sinews B-DNP
and O
bones B-DNP

-DOCSTART- O

bruise B-NEG

-DOCSTART- O

This O
is O
a O
syndrome O
with O
numbness O
and O
a O
pain B-NEG
due O
to O
Wind-Dampness B-NEG
. O

-DOCSTART- O

To O
relieve O
rheumatic B-NEG
conditions I-NEG
, O
and O
to O
remove O
damp-heat B-NEG
. O

-DOCSTART- O

Liver B-DNP
health I-DNP
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Protective O
immunity B-NEU
, O
Liver B-DNP

-DOCSTART- O

Diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
Lipid O
profile O

-DOCSTART- O

To O
cool O
lung B-DNP
, O
release O
discomfort B-NEG
in O
pharynx O
, O
remove O
epidemic B-NEG
evils I-NEG
, O
and O
to O
relieve O
cough B-NEG
. O

-DOCSTART- O

To O
clear O
heat B-NEU
and O
transform O
damp B-NEU
, O
disperse O
accumulation O
and O
relieve O
pain B-NEG
. O

-DOCSTART- O

cold B-NEG
and O
heat B-NEG
; O

cold B-NEG
syndrome I-NEG
and O
heat B-NEG
syndrome I-NEG
two O
of O
the O
eight O
principles O
in O
analysing O
and O
differentiating O
pathological O
conditions O
; O

cold B-NEG
caused O
by O
excess O
of O
Eum O
, O
and O
heat B-NEG
caused O
by O
excess O
of O
Yang O
. O

chills B-NEG
and O
fever B-NEG

cold B-NEG
pathogene I-NEG
and O
heat B-NEG
pathogene I-NEG

-DOCSTART- O

move O
blood B-DNP

-DOCSTART- O

A O
high O
performance O
liquid O
chromatography-hydride O
generation-atomic O
fluorescence O
spectrometry O
( O
HPLC-HG-AFS O
) O
method O
was O
developed O
for O
the O
simultaneous O
determination O
of O
four O
arsenic B-DNP
species I-DNP
( O
As(III) B-DNP
) O
, O
dimethylarsinic B-DNP
acid I-DNP
( O
DMA B-DNP
) O
, O
monomethylarsonic B-DNP
acid I-DNP
( O
MMA B-DNP
) O
and O
arsenate B-DNP
As(V) I-DNP
in O
dog O
plasma O
. O

Good O
separation O
of O
the O
four O
arsenic O
species O
was O
achieved O
within O
15min O
on O
an O
anion-exchange O
column O
with O
isocratic O
elution O
using O
15mmol/L O
KH(2)PO(4 O
) O
( O
pH O
5.9 O
) O
as O
eluent O
at O
a O
flow O
rate O
of O
1.0mL/min O
. O

The O
assay O
was O
linear O
over O
the O
range O
of O
1.25-200 O
, O
1.56-200 O
, O
1.34-172 O
, O
and O
2.50-200ng/mL O
with O
the O
detection O
limits O
of O
0.8 O
, O
1 O
, O
0.86 O
and O
2.00ng/mL O
for O
As O
( O
III O
) O
, O
DMA O
, O
MMA O
and O
As O
( O
V O
) O
, O
respectively O
. O

The O
method O
was O
validated O
for O
selectivity O
, O
precision O
, O
accuracy O
and O
recovery O
and O
then O
applied O
to O
a O
comparative O
pharmacokinetic O
study O
of O
the O
arsenic O
species O
in O
beagle O
dogs O
after O
a O
single O
oral O
administration O
of O
Realgar O
( O
24.32mg/kg O
, O
equivalent O
to O
11.31mgAs/kg O
) O
alone O
or O
Niu O
Huang O
Jie O
Du O
Pian O
(a O
patent O
traditional O
Chinese O
medicine O
( O
TCM O
) O
, O
380mg/kg O
, O
equivalent O
to O
28.45mgAs/kg O
) O
, O
respectively O
. O

DMA B-DNP
was O
found O
to O
be O
the O
predominant O
species O
in O
the O
dog O
plasma O
after O
dosing O
, O
with O
As(V O
) O
appeared O
as O
the O
quickly O
eliminating O
one O
. O

No O
traces O
of O
MMA O
and O
As(III O
) O
were O
detected O
at O
any O
sampling O
time O
points O
. O

The O
main O
pharmacokinetic O
parameters O
found O
for O
DMA O
p.o O
. O
administration O
of O
Realgar O
and O
Niu O
Huang O
Jie O
Du O
Pian O
were O
as O
follows O
: O
C(max O
) O
( O
14.7 O
4.2 O
) O
and O
( O
57 O
32.0)ng/mL O
, O
T(max O
) O
( O
2.4 O
0.5 O
) O
and O
( O
2.5 O
0.5)h O
, O
AUC(0-36 O
) O
( O
151.1 O
12.9 O
) O
and O
( O
635.9 O
418.2)ngh/mL O
, O
AUC(0- O
) O
( O
206 O
44.5 O
) O
and O
( O
687.2 O
425.1)ngh/mL O
, O
t(1/2 O
) O
( O
16.2 O
7.9 O
) O
and O
( O
9.4 O
2.2)h O
, O
respectively O
. O

The O
influence O
of O
compounding O
in O
Niu O
Huang O
Jie O
Du O
Pian O
on O
the O
pharmacokinetics O
of O
arsenics O
was O
shown O
with O
increased O
transformation O
of O
DMA O
and O
its O
faster O
elimination O
rate O
. O

-DOCSTART- O

promote O
the O
intestine B-DNP

-DOCSTART- O

Stagnation O
of O
qi O
and O
blood B-NEU
marked O
by O
chest B-NEG
pain I-NEG
; O
dry B-NEG
cough I-NEG
with O
shortness B-NEG
of I-NEG
breath I-NEG
; O
insomnia B-NEG
. O

-DOCSTART- O

invigorate O
blood B-NEU
and O
regulate O
menstruation B-NEU

-DOCSTART- O

Saengmaeksan O
inhibits O
inflammatory B-POS
mediators I-POS
by O
suppressing O
RIP-2 B-NEU
/ I-NEU
caspase-1 I-NEU
activation I-NEU
. O

-DOCSTART- O

gases B-NEG
retention I-NEG
in I-NEG
the I-NEG
lungs I-NEG

-DOCSTART- O

Treatment O
of O
cough B-NEG
, O
asthma B-NEG
and O
distending B-NEG
pain I-NEG
of O
the O
chest O
caused O
by O
cold B-NEG
phlegm I-NEG
, O
arthralgia B-NEG
accompanied I-NEG
by O
numbness B-NEG
due O
to O
obstruction O
of O
collaterals O
by O
phlegm B-NEG
, O
deep B-NEG
abscess I-NEG
. O

-DOCSTART- O

Rikkunshito O
, O
an O
herbal O
medicine O
, O
suppresses O
cisplatin-induced O
anorexia B-NEG
in O
rats O
via O
5-HT2 O
receptor O
antagonism O
. O

-DOCSTART- O

release O
muscles B-DNP

-DOCSTART- O

dribbling B-NEG
urination I-NEG
; O
dribbling B-NEG
of I-NEG
urine I-NEG

-DOCSTART- O

Recently O
, O
also O
used O
for O
biliary B-NEG
ascariasis I-NEG
, O
biliary B-NEG
infection I-NEG
and O
cholelithiasis B-NEG
with O
abdominal O
pain B-NEG
( O
adhesive O
ascarial O
and O
paralytic B-NEG
ileus I-NEG
) O
. O

-DOCSTART- O

attack O
and O
expel O

-DOCSTART- O

For O
the O
treatment O
of O
adult O
patients O
diagnosed O
with O
anaplastic B-NEG
astrocytoma I-NEG
whose O
disease O
has O
progressed O
after O
therapy O
with O
nitrosourea O
and O
procarbazine O
, O
as O
well O
as O
concomitantly O
with O
radiation O
therapy O
for O
treatment O
of O
newly O
diagnosed O
glioblastoma B-NEG
multiforme I-NEG
. O
Also O
used O
as O
maintenance O
therapy O
for O
glioblastoma B-NEG
multiforme I-NEG
. O

-DOCSTART- O

Keishibukuryogan O
ameliorates O
glucose B-NEG
intolerance I-NEG
and O
hyperlipidemia B-NEG
in O
Otsuka O
Long-Evans O
Tokushima O
Fatty O
( O
OLETF O
) O
rats O
. O

-DOCSTART- O

abdominal B-NEG
pain I-NEG

-DOCSTART- O

diarrhea B-NEG

-DOCSTART- O

Chronic B-NEG
Hepatitis I-NEG
B I-NEG
Virus I-NEG

-DOCSTART- O

Epinastine O
has O
a O
multiaction O
effect O
that O
inhibits O
the O
allergic B-NEU
response I-NEU
in O
3 O
ways O
: O
1 O
stabilizes O
mast B-DNP
cells I-DNP
by O
preventing O
mast B-NEU
cell I-NEU
degranulation I-NEU
to O
control O
the O
allergic B-NEU
response I-NEU
, O
2 O
prevents O
histamine B-DNP
binding O
to O
both O
the O
H1- O
and O
H O
2-receptors O
to O
stop O
itching B-NEG
and O
provide O
lasting B-POS
protection I-POS
, O
and O
3 O
prevents O
the O
release B-NEU
of I-NEU
proinflammatory I-NEU
chemical I-NEU
mediators I-NEU
from O
the O
blood O
vessel O
to O
halt O
progression O
of O
the O
allergic B-NEU
response I-NEU
. O

-DOCSTART- O

Fluticasone O
, O
a O
synthetic O
trifluorinated O
glucocorticoid O
receptor O
agonist O
with O
antiallergic O
, O
anti-inflammatory O
and O
antipruritic O
effects O
. O

Prazosin O
acts O
by O
inhibiting O
the O
postsynaptic B-DNP
alpha(1)-adrenoceptors I-DNP
on O
vascular O
smooth O
muscle O
. O

This O
inhibits O
the O
vasoconstrictor B-NEU
effect I-NEU
of O
circulating O
and O
locally O
released O
catecholamines O
, O
resulting O
in O
peripheral B-NEU
vasodilation I-NEU
. O

Oxymetazoline O
is O
a O
direct O
acting O
sympathomimetic O
amine O
, O
which O
acts O
on O
alpha-adrenergic O
receptors O
in O
the O
arterioles O
of O
the O
conjunctiva O
and O
nasal O
mucosa O
. O

-DOCSTART- O

the O
low B-NEG
back I-NEG
and I-NEG
knees I-NEG
being I-NEG
aching I-NEG
and O
limp(i B-NEG
. O
e O
. O
, O
weak B-NEG
) O

-DOCSTART- O

To O
induce O
subsidence O
of O
swelling B-NEG
and O
remove O
toxic B-NEG
substances O
, O
to O
cause O
purgation B-NEG
. O

-DOCSTART- O

jaundice B-NEG
a O
morbid B-NEG
condition I-NEG
clinically O
characterized O
by O
yellow-brown B-NEG
pigmentation I-NEG
of I-NEG
the I-NEG
skin I-NEG
and I-NEG
sclera I-NEG
and O
dark B-NEG
yellow I-NEG
colored I-NEG
urine I-NEG
, O
and O
classified O
into O
two O
types O
, O
Yang O
jaundice B-NEG
and O
Eum O
jaundice B-NEG
; O
one O
of O
the O
five O
types O
of O
jaundice B-NEG
. O

-DOCSTART- O

Vaccination O
of O
humans O
with O
CYT006-AngQb O
has O
been O
shown O
to O
induce O
angiotensin B-DNP
II I-DNP
specific O
antibodies O
that O
should O
inhibit O
binding O
of O
angiotensin B-DNP
II I-DNP
to O
its O
receptors O
and O
thus O
reduce O
the O
narrowing O
of O
blood B-DNP
vessels I-DNP
. O

-DOCSTART- O

tonify O
marrow B-DNP

-DOCSTART- O

Treatment O
of O
impotence O
and O
seminal B-NEU
emission I-NEU
, O
mass O
in O
the O
abdomen B-DNP
, O
scrofula B-NEG
, O
traumatic B-NEG
injuries I-NEG
, O
external O
use O
for O
carbuncles B-NEG
and O
boils B-NEG
. O

-DOCSTART- O

Eye B-DNP
, O
Mood O
, O
Physical B-DNP
performance I-DNP
and O
fitness O
, O
Eye B-DNP
health I-DNP
, O
Eye B-DNP
health I-DNP
, O
Others O
, O
Diet O
related O
cardiovascular B-NEG
disease I-NEG
, O
Strength O
and O
power O
, O
Intelligence B-POS
, O
Hemostatic B-POS
function I-POS
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP

-DOCSTART- O

This O
is O
a O
symptom O
with O
fullness B-NEU
and O
pain B-NEG
in O
the O
chest O
and O
abdomen O
. O

-DOCSTART- O

Bleeding B-NEG
due O
to O
blood B-NEU
heat I-NEU
, O
amenorrhea B-NEG
due O
to O
blood B-NEG
stasis I-NEG
, O
knocks O
and O
falls O
, O
impediment O
pain B-NEG
in O
joints O
. O

-DOCSTART- O

Interferon O
alpha O
binds O
to O
type O
I O
interferon O
receptors O
which O
activate O
two O
Jak1 O
and O
Tyk2 O
and O
activate O
multiple O
dowmstream O
immunomodulatory B-NEU
and O
antiviral O
proteins O
. O

Ribavirin O
triphosphate O
is O
a O
potent O
competitive O
inhibitor O
of O
inosine O
monophosphate O
dehydrogenase O
, O
viral O
RNA O
polymerase O
and O
mRNA O
guanylyltransferase O
( O
viral O
) O
and O
can O
be O
incorporated O
into O
RNA O
in O
RNA O
viral O
species O
. O

Telaprevir O
is O
an O
inhibitor O
of O
the O
HCV B-DNP
NS3/4A I-DNP
serine I-DNP
protease I-DNP
, O
necessary O
for O
the O
proteolytic O
cleavage O
of O
the O
HCV O
encoded O
polyprotein O
into O
mature O
forms O
of O
the O
NS4A O
, O
NS4B O
, O
NS5A O
and O
NS5B O
proteins O
and O
essential O
for O
viral O
replication O
. O

-DOCSTART- O

Genz-112638 O
, O
a O
novel O
ceramide O
analog O
given O
orally O
, O
is O
designed O
to O
inhibit O
the O
enzyme B-DNP
glucosylceramide I-DNP
synthase I-DNP
, O
which O
results O
in O
reduced O
production O
of O
glucocerebroside B-DNP
. O

This O
is O
the O
substance O
that O
builds O
up O
in O
the O
cells O
and O
tissues O
of O
people O
with O
Gaucher B-NEG
disease I-NEG
. O

In O
preclinical O
studies O
, O
the O
molecule O
has O
shown O
high O
potency O
and O
specificity O
. O

-DOCSTART- O

alleviate O
edema B-NEG

-DOCSTART- O

insubstantial O
wind B-NEG

-DOCSTART- O

Zuo O
Jin O
Wan O
( O
ZJW O
) O
, O
a O
typical O
traditional O
Chinese O
medicine O
( O
TCM O
) O
formula O
, O
has O
been O
identified O
to O
have O
anticancer B-POS
activity I-POS
in O
recent O
studies O
. O

In O
this O
study O
, O
we O
determined O
the O
underlying O
mechanism O
of O
ZJW O
in O
the O
reversal O
effect O
of O
multidrug O
resistance O
on O
colorectal B-NEG
cancer I-NEG
in O
vitro O
and O
in O
vivo O
. O

Our O
results O
showed O
that O
ZJW O
significantly O
enhanced O
the O
sensitivity O
of O
chemotherapeutic O
drugs O
in O
HCT116/L-OHP O
, O
SGC7901/DDP O
, O
and O
Bel/Fu O
MDR O
cells O
. O

Moreover O
, O
combination O
of O
chemotherapy O
with O
ZJW O
could O
reverse O
the O
drug O
resistance O
of O
HCT116/L-OHP B-DNP
cells I-DNP
, O
increase O
the O
sensitivity O
of O
HCT116/L-OHP B-DNP
cells I-DNP
to O
L-OHP O
, O
DDP O
, O
5-Fu O
, O
and O
MMC O
in O
vitro O
, O
and O
inhibit O
the O
tumor B-NEG
growth I-NEG
in O
the O
colorectal O
MDR O
cancer O
xenograft O
model O
. O

ICP-MS O
results O
showed O
that O
ZJW O
could O
increase O
the O
concentration O
of O
chemotherapeutic O
drugs O
in O
HCT116/L-OHP O
cells O
in O
a O
dose-dependent O
manner O
. O

Furthermore O
, O
we O
showed O
that O
ZJW O
could O
reverse O
drug O
resistance O
of O
colorectal B-NEG
cancer I-NEG
cells O
by O
decreasing O
P-gp B-NEU
level I-NEU
in O
vitro O
and O
in O
vivo O
, O
which O
has O
been O
represented O
as O
one O
of O
the O
major O
mechanisms O
that O
contribute O
to O
the O
MDR B-NEG
phenotype I-NEG
. O

Our O
study O
has O
provided O
the O
first O
direct O
evidence O
that O
ZJW O
plays O
an O
important O
role O
in O
reversing O
multidrug B-NEG
resistance I-NEG
of O
human O
colorectal B-NEG
cancer I-NEG
and O
may O
be O
considered O
as O
a O
useful O
target O
for O
cancer O
therapy O
. O

-DOCSTART- O

To O
remove O
phlegm B-NEG
, O
disperse O
the O
lumps O
, O
detoxify O
and O
relieve O
swelling B-NEG
. O

-DOCSTART- O

recurrent O
fever B-NEG
by O
the O
exhaustion B-NEG
after O
healing O
from O
pyogenic B-NEG
febrile I-NEG
disease I-NEG
. O

-DOCSTART- O

For O
the O
treatment O
of O
the O
signs O
and O
symptoms O
of O
idiopathic O
Parkinson's B-NEG
disease I-NEG
. O
Also O
used O
for O
the O
treatment O
of O
restless B-NEG
legs I-NEG
syndrome I-NEG
. O

-DOCSTART- O

a O
lumbago B-NEG
pain I-NEG
. O

Occur O
by O
invasion B-NEG
of I-NEG
wind-heat I-NEG
in O
kidney O
meridian O
. O

-DOCSTART- O

To O
stop O
pain B-NEG

-DOCSTART- O

major O
cold B-NEG
and O
heat B-NEU

-DOCSTART- O

dyspepsia B-NEG
; O
indigestion B-NEG

-DOCSTART- O

In O
addition O
, O
dalbavancin O
alters O
bacterial-cell-membrane O
permeability O
and O
RNA B-DNP
synthesis I-DNP
. O

-DOCSTART- O

1 O
For O
cases O
of O
malaria B-NEG
with O
splenomegaly B-NEG
, O
epicgastric B-NEG
fullness I-NEG
, O
whitish B-NEG
fur I-NEG
on I-NEG
the I-NEG
tongue I-NEG
, O
wiry B-NEG
pulse I-NEG
, O
which O
are O
attributive O
to O
dysfunction B-NEG
of I-NEG
spleen I-NEG
and O
stagnation O
of O
vital O
energy O
and O
blood O
, O
omit O
Glycyrrhizae O
and O
add O
Ramulus O
cinnamoni O
, O
carapax O
trionycis O
to O
ac O

-DOCSTART- O

absorption O
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Digestion B-NEU
, O
motility O
, O
Others O

-DOCSTART- O

Wind-evil O
attacked O
meridian O
, O
facial B-NEG
paralysis I-NEG
, O
muscle B-NEG
numbness I-NEG
, O
pain B-NEG
of I-NEG
tendons I-NEG
and I-NEG
bone I-NEG
. O

-DOCSTART- O

Acetaminophen O
acts O
primarily O
in O
the O
CNS O
, O
by O
increasing O
the O
pain B-NEG
threshold O
by O
inhibiting O
both O
isoforms O
of O
cyclooxygenase O
, O
COX-1 O
, O
COX-2 O
, O
and O
COX-3 O
enzymes O
involved O
in O
prostaglandin B-DNP
( I-DNP
PG I-DNP
) I-DNP
synthesis I-DNP
. O

-DOCSTART- O

Weak B-NEG
and O
reduced O
yin O
blood B-DNP
after O
treatment O
, O
exterior O
evil O
, O
loss B-NEG
of I-NEG
blood I-NEG
, O
cold B-NEG
and O
period O
, O
headache B-NEG
, O
hot B-NEU
body I-NEU
, O
feeling O
slightly O
cold B-NEG
, O
no O
sweating B-NEG
. O

-DOCSTART- O

To O
kill O
worms B-NEG
. O

-DOCSTART- O

deficiency O
of O
Gi O
( O
vital O
energy O
) O
of O
the O
stomach O

-DOCSTART- O

clear O
heat B-NEU
and O
relieve O
toxicity B-NEG

-DOCSTART- O

1 O
Applicable O
to O
edema B-NEG
of I-NEG
wind I-NEG
type O
attributive O
to O
attack O
of O
dampness B-NEU
and O
heat B-NEU
, O
which O
is O
manifested O
as O
general O
edema O
beginning O
from O
the O
eyelids O
, O
dyuria B-NEG
, O
fever B-NEG
, O
chilliness B-NEG
, O
white B-NEG
and I-NEG
greasy I-NEG
fur I-NEG
on O
the O
tongue O
and O
slow B-NEG
pulse I-NEG
. O
2 O
Also O
applicable O
to O
urinar B-NEU

-DOCSTART- O

To O
replenish O
the O
kidney B-DNP
, O
to O
strengthen O
the O
bones B-DNP
, O
to O
promote O
the O
healing B-POS
of I-POS
fracture I-POS
, O
and O
to O
relieve O
pain B-NEG
. O

-DOCSTART- O

expel O
malign B-DNP
blood I-DNP

-DOCSTART- O

To O
benefit O
qi O
; O
To O
soothe O
stomach B-DNP
; O
To O
reduce O
lump B-NEG
; O
To O
stop O
vomiting B-NEG

-DOCSTART- O

To O
cause O
diuresis B-NEU
, O
to O
invigorate O
the O
spleen B-DNP
function I-DNP
, O
and O
to O
calm O
the O
mind B-NEU
. O

-DOCSTART- O

nourish O
essence-marrow B-NEU

-DOCSTART- O

1 O
Morellic B-NEU
acid I-NEU
, O
one O
of O
its O
components O
, O
inhibits O
Ehrljch-Ascites B-NEG
tumour I-NEG
and O
sarcoma180 B-NEG
. O

2 O
Inhibiting O
BEL-7402 B-DNP
species I-DNP
of O
hepatic B-NEG
cancer I-NEG
cells I-NEG
and O
HeLa B-DNP
cells I-DNP
in O
vitro O
. O

3 O
Increasing O
white B-DNP
blood I-DNP
cells I-DNP
and O
promoting O
its O
phagocytosis B-NEU
during O
the O
treatment O
of O
cancer B-NEG
in O
experimental O
animals O

-DOCSTART- O

Once O
bound O
, O
the O
receptor/ligand O
complex O
localizes O
to O
the O
nucleus O
and O
acts O
as O
a O
DNA O
binding O
transcription O
factor O
, O
regulating O
gene O
expression O
. O

-DOCSTART- O

promote O
liquid B-NEU

-DOCSTART- O

inner O
impairment B-NEG

-DOCSTART- O

Its O
component O
oleanolic O
acid O
can O
prevent O
and O
relieve O
cyclophosphamide-induced B-NEG
leukocytopenia I-NEG
in O
mice O
. O

Enhancing O
the O
anoxia B-NEU
tolerance I-NEU
of O
mice O
under O
atmospheric O
pressure O
. O

Increasing O
coronary B-NEU
flow I-NEU
in O
rabbits O
in O
vitro O
. O

Relaxing O
adrenaline-induced B-NEU
vasocontricyion I-NEU
in O
rabbits O
in O
vitro O
. O

Lowering O
the O
level O
of O
blood B-DNP
lipid I-DNP
. O

-DOCSTART- O

settle O
the O
pain B-NEG

-DOCSTART- O

Treatment O
of O
measles B-NEG
without O
adequate O
eruption B-NEG
, O
urticaria B-NEG
with O
itching B-NEG
, O
edema B-NEG
with O
oliguria B-NEG
. O

-DOCSTART- O

Clarithromycin O
is O
first O
metabolized O
to O
14-OH O
clarithromycin O
, O
which O
is O
active O
and O
works O
synergistically O
with O
its O
parent O
compound O
. O

-DOCSTART- O

Treatment O
of O
stagnation O
of O
qi O
of O
the O
liver B-DNP
and O
stomach B-DNP
marked O
by O
distension O
and O
pain B-NEG
in O
the O
chest O
and O
hypochondriac B-NEG
regions O
, O
stuffiness B-NEG
feeling O
in O
the O
stomach O
, O
anorexia B-NEG
and O
vomiting B-NEG
. O

-DOCSTART- O

Acute B-NEG
Lymphoblastic I-NEG
Leukemia I-NEG

-DOCSTART- O

To O
promote O
diuresis B-NEU
, O
treat O
stranguria B-NEG
, O
remove O
urinary B-NEG
calculus I-NEG
. O

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk O
, O
Body B-NEU
weight I-NEU
regulation I-NEU
, O
Body B-NEU
weight I-NEU

-DOCSTART- O

To O
contract O
uterus B-DNP
and O
stanch O
bleeding B-NEG
, O
relieve O
pain B-NEG
. O

-DOCSTART- O

bloody O
stool B-NEG
; O
hematochezia B-NEG

-DOCSTART- O

strengthen O
tooth B-DNP

-DOCSTART- O

snake-bite B-NEG

-DOCSTART- O

AIM O
: O
Zhi O
Zhu O
Wan O
( O
ZZW O
) O
is O
a O
classical O
Chinese O
medical O
formulation O
used O
for O
the O
treatment O
of O
functional O
dyspepsia B-NEG
that O
attributed O
to O
Spleen B-NEG
- I-NEG
deficiency I-NEG
Syndrome I-NEG
. O

ZZW O
contains O
Atractylodes O
Rhizome O
and O
Fructus O
Citrus O
Immaturus O
, O
the O
later O
originates O
from O
both O
Citrus O
aurantium O
L. O
( O
BZZW O
) O
and O
Citrus O
sinensis O
Osbeck O
( O
RZZW O
) O
. O

The O
present O
study O
is O
designed O
to O
elucidate O
disparities O
in O
the O
clinical O
efficacy O
of O
two O
ZZW O
varieties O
based O
on O
the O
pharmacokinetics O
of O
naringenin O
and O
hesperetin O
. O

MEHTOD O
: O
After O
oral O
administration O
of O
ZZWs O
, O
blood O
sample O
was O
collected O
from O
healthy O
volunteers O
at O
designed O
time O
points O
. O

Naringenin O
and O
hesperetin O
were O
detected O
in O
plasma O
by O
RP-HPLC O
, O
pharmacokinetic O
parameters O
were O
processed O
using O
mode-independent O
methods O
with O
WINNONLIN O
. O

RESULTS O
: O
After O
oral O
administration O
of O
BZZW O
, O
both O
naringenin O
and O
hesperetin O
were O
detected O
in O
plasma O
, O
and O
demonstrated O
similar O
pharmacokinetic O
parameters O
. O

Ka O
was O
0.384+/-0.165 O
and O
0.401+/-0.159 O
, O
T(1/2(ke))(h O
) O
was O
5.491+/-3.926 O
and O
5.824+/-3.067 O
, O
the O
AUC O
( O
mg/Lh O
) O
was O
34.886+/-22.199 O
and O
39.407+/-19.535 O
for O
naringenin O
and O
hesperetin O
, O
respectively O
. O

However O
, O
in O
the O
case O
of O
RZZW O
, O
only O
hesperetin O
was O
found O
in O
plasma O
, O
but O
the O
pharmacokinetic O
properties O
for O
hesperetin O
in O
RZZW O
was O
different O
from O
that O
in O
BZZW O
. O

T(max O
) O
for O
hesperetin O
in O
RZZW O
is O
about O
8.515h O
, O
and O
its O
C(max O
) O
is O
much O
larger O
than O
that O
of O
BZZW O
. O

Moreover O
, O
it O
was O
eliminated O
slowly O
as O
it O
possessed O
a O
much O
larger O
AUC O
value O
. O

CONCLUSION O
: O
The O
distinct O
therapeutic O
orientations O
of O
the O
Chinese O
medical O
formula O
ZZWs O
with O
different O
Fructus O
Citrus O
Immaturus O
could O
be O
elucidated O
based O
on O
the O
pharmacokinetic O
parameters O
of O
constituents O
after O
oral O
administration O
. O

-DOCSTART- O

Intraabdominal B-NEG
Infections I-NEG

-DOCSTART- O

excessive B-NEG
thought I-NEG
; O
anxiety B-NEG

-DOCSTART- O

erysipelas B-NEG
acute O
infection B-NEG
of O
the O
skin O
characterized O
by O
sudden O
onset O
of O
local O
bright O
red O
coloration O
and O
swelling B-NEG
with O
rapid O
spreading O
. O

-DOCSTART- O

smallpox B-NEG

-DOCSTART- O

calm O
five O
viscera B-DNP

-DOCSTART- O

Enteritis B-NEG
, O
dysentery B-NEG
, O
prolapse B-NEG
of O
rectum O
, O
emission B-NEG
, O
knocks B-NEG
and O
falls B-NEG
. O

-DOCSTART- O

Ankylosing B-NEG
Spondylitis I-NEG

-DOCSTART- O

Some O
patients O
with O
major B-NEG
depressive I-NEG
disorder I-NEG
( O
MDD B-NEG
) O
do O
not O
show O
remission O
of O
their O
depressive O
symptomatology O
. O

We O
investigated O
the O
efficacy O
of O
Rokumigan O
( O
TJ-87 O
) O
and O
Hachimijiogan O
( O
TJ-7 O
) O
in O
20 O
patients O
with O
prolonged O
partial O
remitted O
MDD B-NEG
associated O
with O
fatigue B-NEG
or O
loss B-NEG
of I-NEG
energy I-NEG
. O

In O
these O
20 O
patients O
, O
TJ-7 O
or O
TJ-87 O
was O
added O
to O
the O
previous O
regimen O
for O
4 O
weeks O
. O

Six O
patients O
were O
'much O
improved' O
, O
six O
were O
'minimally O
improved' O
( O
responders O
) O
, O
and O
eight O
showed O
'no O
change' O
( O
non-responders O
) O
, O
on O
the O
Clinical O
Global O
Impression O
Global O
Improvement O
scale O
. O

All O
responders O
had O
Shofuku-fujin O
( O
tenderness B-NEG
or I-NEG
weakness I-NEG
of I-NEG
the I-NEG
lower I-NEG
abdomen I-NEG
) O
. O

In O
conclusion O
, O
we O
experienced O
12 O
outpatients O
with O
prolonged O
partial O
remitted O
MDD B-NEG
with O
fatigue B-NEG
or O
loss B-NEG
of I-NEG
energy I-NEG
, O
which O
was O
successfully O
treated O
with O
TJ-87 O
or O
TJ-7 O
. O

-DOCSTART- O

This O
is O
a O
symptom O
that O
the O
body O
becomes O
haggard O
because O
of O
exhaustion B-NEG
syndrome I-NEG
. O

-DOCSTART- O

night B-NEG
sweat I-NEG
; O
night B-NEG
sweating I-NEG
spontaneous O
sweating B-NEU
during O
asleep O
and O
no O
sweating B-NEU
while O
awake O
, O
chiefly O
caused O
by O
deficiency B-NEG
of O
vital O
essence O
and O
presence O
of O
internal O
heat O
. O

-DOCSTART- O

burn B-NEG

-DOCSTART- O

invigorate O
blood B-NEU
and O
relieve O
pain B-NEG

-DOCSTART- O

Wind-damp B-NEG
impediment O
pain B-NEG
, O
flooding B-NEG
, O
vaginal B-NEG
discharge I-NEG
, O
pharyngolaryngitis B-NEG
, O
mammary B-NEG
welling I-NEG
abscess I-NEG
, O
knocks B-NEG
and O
falls B-NEG
, O
poisonous B-NEG
snake I-NEG
bite I-NEG
. O

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Protective O
immunity B-NEU

-DOCSTART- O

( O
1 O
) O
diarrhea B-NEG
( O
2 O
) O
diarrhea B-NEG
and O
urination B-NEG
( O
3 O
) O
diarrhea B-NEG
and O
dysentery B-NEG

-DOCSTART- O

promote O
water O
and O
purge O
/ O
relieve O
toxicity B-NEG
and O
alleviate O
edema B-NEG

-DOCSTART- O

To O
expel O
wind B-NEG
from O
the O
body O
surface O
, O
clear O
away O
heat B-NEU
and O
promote O
bowel B-NEU
movement I-NEU
. O

-DOCSTART- O

Treatment O
of O
edema B-NEG
with O
oliguria B-NEG
, O
dizziness B-NEG
and O
palpitation B-NEG
caused O
by O
retained O
fluid O
, O
diminished O
function O
of O
the O
spleen B-DNP
marked O
by O
anorexia B-NEG
, O
loose O
stools B-NEG
or O
diarrhea B-NEG
, O
restlessness B-NEG
and O
insomnia B-NEG
. O

-DOCSTART- O

profuse O
bleeding B-NEG
after O
delivery B-NEU

-DOCSTART- O

weakness B-NEG
of I-NEG
the I-NEG
spleen I-NEG
and I-NEG
stomach I-NEG

-DOCSTART- O

This O
is O
a O
symptom O
with O
stuffiness B-NEG
and O
hot B-NEG
in O
the O
chest O
and O
abdomen O
. O

-DOCSTART- O

Eum O
deficiency B-NEG
of I-NEG
liver I-NEG
and I-NEG
kidney I-NEG
; O
deficiency O
of O
Eum(vital O
essence O
) O
of O
the O
liver B-DNP
and O
kidney B-DNP

-DOCSTART- O

Zidovudine O
inhibits O
the O
activity O
of O
HIV-1 O
reverse O
transcriptase O
( O
RT O
) O
via O
DNA O
chain O
termination O
after O
incorporation O
of O
the O
nucleotide O
analogue O
. O

-DOCSTART- O

swollen O
check O
, O
mumps B-NEG
; O
epidemic B-NEG
parotitis I-NEG

-DOCSTART- O

Toxoplasmosis B-NEG

-DOCSTART- O

bald B-NEG
white I-NEG
scalp I-NEG
sore I-NEG
; O
tinea B-NEG
alba I-NEG
; O
white B-NEG
ringworm I-NEG

-DOCSTART- O

1 O
Oral O
administration O
increases O
the O
level O
of O
cAMP B-DNP
and O
decrease O
the O
level O
of O
cGMP B-NEU
in I-NEU
plasma I-NEU
and O
in O
leukocytes O
. O
Protect O
the O
liver B-DNP
from O
damage O
. O
Hypotensive B-NEG
. O

-DOCSTART- O

Treatment O
of O
palpitation B-NEG
and O
insomnia B-NEG
, O
convulsion B-NEG
, O
epilepsy B-NEG
, O
nebula B-NEG
, O
skin B-NEG
ulcerations I-NEG
difficult O
to O
heal O
. O

-DOCSTART- O

To O
reduce O
masses B-NEG
by O
dissipating O
blood B-NEG
stasis I-NEG
, O
and O
to O
relieve O
pain B-NEG
by O
removing O
stagnancy B-NEG
of O
food O
. O

-DOCSTART- O

Chronic B-NEG
Heart I-NEG
Failure I-NEG

-DOCSTART- O

Investigated O
for O
use/treatment O
in O
depression B-NEG
. O

-DOCSTART- O

Retention O
of O
moisture O
, O
dermatological B-DNP
systems I-DNP
health I-DNP

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
Body B-NEU
weight I-NEU
regulation I-NEU
, O
Improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
Liver B-DNP
, O
Liver B-DNP
health I-DNP

-DOCSTART- O

pain B-NEG
of O
back O
and O
vertebra O

-DOCSTART- O

Beginning O
stage O
of O
rash B-NEG
, O
fever B-NEG
, O
cough B-NEG
, O
alternating O
cold B-NEU
and I-NEU
hot I-NEU
feeling I-NEU

-DOCSTART- O

General O
Anesthetic O
Drug O
Adverse O
Reaction O

-DOCSTART- O

tenesmus B-NEG

-DOCSTART- O

Chunghyuldan O
( O
Daio-Orengedokuto O
in O
Japanese O
) O
( O
CHD O
) O
has O
been O
used O
as O
an O
antihyperlipidemic B-NEG
and O
antiischemic O
agent O
in O
Korea O
. O

To O
evaluate O
in O
vitro O
the O
efficacy O
of O
Chunghyuldans O
( O
CHDs O
) O
metabolized O
with O
and O
without O
human O
intestinal B-DNP
microflora I-DNP
against O
brain B-NEG
ischemia I-NEG
, O
we O
investigated O
its O
anti-inflammatory B-POS
effect I-POS
on O
LPB-induced O
RAW264.7 O
cells O
. O

Both O
metabolized O
CHD O
( O
MCHD O
) O
and O
CHD O
showed O
antioxidant B-NEU
activities I-NEU
in O
vitro O
, O
and O
inhibited O
nitric B-DNP
oxide I-DNP
( O
NO B-DNP
) O
and O
prostaglandin B-DNP
E2 I-DNP
( O
PGE2 B-DNP
) O
productions O
in O
lipopolysaccharide O
( O
LPS)-induced O
RAW264.7 O
cells O
. O

These O
also O
inhibited O
enzyme B-NEU
activities I-NEU
and O
protein B-NEU
expressions I-NEU
of O
inducible O
NO B-DNP
synthase I-DNP
and O
cyclooxygenase-2 B-DNP
in O
LPB-induced O
RAW264.7 O
cells O
. O

MCHD-inhibitory O
activity O
against O
NO B-NEU
and I-NEU
PGE2 I-NEU
productions I-NEU
in O
LPB-induced O
RAW264.7 O
cells O
was O
more O
potent O
than O
those O
of O
CHD O
. O

These O
results O
suggest O
that O
CHD O
may O
show O
potent O
anti-inflammatory B-POS
activity I-POS
in O
vivo O
and O
can O
improve O
brain B-NEG
ischemia I-NEG
. O

-DOCSTART- O

urticaria B-NEG

-DOCSTART- O

stop O
thirst B-NEU

-DOCSTART- O

Dermatological B-DNP
systems I-DNP
health I-DNP
, O
General O
skin B-DNP
health I-DNP
, O
Others O

-DOCSTART- O

Hyperlipidemia B-NEG

-DOCSTART- O

linear O
lump B-NEG
of I-NEG
scrofula I-NEG

-DOCSTART- O

blood B-NEG
vomiting I-NEG
due O
to O
weakness B-NEG
and O
fatigue B-NEG

-DOCSTART- O

Swelling B-NEG
and O
pain B-NEG
due O
to O
blood B-NEG
stagnation I-NEG
caused O
by O
external B-NEG
injuries I-NEG
. O

-DOCSTART- O

disease O
due O
to O
wind-dampness B-NEG
; O
rheumatism B-NEG

-DOCSTART- O

1 O
To O
clear O
heat B-NEU
and O
toxic B-NEG
material O
. O
2 O
To O
clear O
liver-heat B-NEU
to O
treat O
eye B-NEG
disease I-NEG
. O
3 O
To O
clear O
dampness-heat B-NEU
. O

-DOCSTART- O

metrorrhagia B-NEG

-DOCSTART- O

Arrhythmia B-NEG

-DOCSTART- O

wind O
one O
of O
the O
five O
pathogenic O
factors O
, O
also O
one O
of O
the O
six O
exogenous O
pathogenic O
factors O
which O
often O
causes O
disease O
in O
association O
with O
other O
pathogenic O
agent O
. O
It O
is O
of O
Yang O
nature O
and O
apt O
to O
change O
, O
resulting O
symptoms O
are O
usually O
migratory O
and O
variable O
. O

-DOCSTART- O

night B-NEG
sweat I-NEG
and O
nocturnal B-NEU
emission I-NEU

-DOCSTART- O

soften O
hard O
mass O

-DOCSTART- O

Oxamniquine O
may O
associate O
with O
an O
irreversible O
inhibition O
of O
the O
nucleic B-NEU
acid I-NEU
metabolism I-NEU
of I-NEU
the I-NEU
parasites I-NEU
. O

A O
hypothesis O
has O
been O
put O
forth O
that O
the O
drug O
is O
activated O
by O
a O
single O
step O
, O
in O
which O
a O
schistosome O
sulfotransferase O
enzyme O
converts O
oxamniquine O
into O
an O
ester O
( O
probably O
acetate O
, O
phosphate O
, O
or O
sulfate O
) O
. O

Subsequently O
, O
the O
ester O
spontaneously O
dissociates O
, O
the O
resulting O
electrophilic O
reactant O
is O
capable O
of O
alkylation O
of O
schistosome O
DNA O
. O

-DOCSTART- O

Dilating O
the O
coronary B-DNP
artery I-DNP
and O
blood B-DNP
vessels I-DNP
of O
hind O
legs O
in O
dogs O
. O

Lowering O
blood B-NEU
pressure I-NEU
transiently O
. O

Inhibiting O
the O
intestines B-DNP
in O
rabbits O
in O
vitro O
. O

Its O
component O
paeoniflorin O
inhibits O
the O
central B-DNP
nervous I-DNP
systems I-DNP
. O

-DOCSTART- O

prolapse B-NEG
of I-NEG
the I-NEG
rectum I-NEG

-DOCSTART- O

abdominal B-NEG
pain I-NEG
due O
to O
intestinal B-NEG
parasitosis I-NEG
; O
abdominal B-NEG
pain I-NEG
due O
to O
intestinal B-NEG
ascariasis I-NEG

-DOCSTART- O

Enfuvirtide O
binds O
to O
the O
first O
heptad-repeat O
( O
HR1 O
) O
in O
the O
gp41 O
subunit O
of O
the O
viral O
envelope O
glycoprotein O
and O
prevents O
the O
conformational B-NEU
changes I-NEU
required O
for O
the O
fusion O
of O
viral O
and O
cellular B-DNP
membranes I-DNP
. O

It O
works O
by O
disrupting O
the O
HIV-1 B-NEG
molecular I-NEG
machinery I-NEG
at O
the O
final O
stage O
of O
fusion O
with O
the O
target O
cell O
, O
preventing O
uninfected B-DNP
cells I-DNP
from O
becoming O
infected O
. O

Enfuvirtide O
is O
a O
biomimetic O
peptide O
that O
was O
rationally O
designed O
to O
mimic O
components O
of O
the O
HIV-1 O
fusion O
machinery O
and O
displace O
them O
, O
preventing O
normal O
fusion O
. O

-DOCSTART- O

Kallmann B-NEG
Syndrome I-NEG

-DOCSTART- O

dry O
cough B-NEG
due O
to O
lung-heat B-NEU

-DOCSTART- O

Used O
to O
provide O
skeletal B-POS
muscle I-POS
relaxation I-POS
as O
an O
adjunct O
to O
general B-NEU
anesthesia I-NEU
, O
for O
endotracheal O
intubation O
or O
to O
facilitate O
mechanical O
ventilation O
. O

-DOCSTART- O

Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
Eldery O
, O
Endocrine B-DNP
system I-DNP
, O
Intelligence B-POS
, O
Others O
, O
Memory B-DNP
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
Body B-NEU
weight I-NEU
regulation I-NEU
, O
Improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
Hemostatic B-DNP
function I-DNP
, O
Diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG

-DOCSTART- O

Swelling B-NEG
pain I-NEG
in O
throat O
, O
red B-NEG
eyes I-NEG
with O
gall O
, O
lung O
heat O
cough B-NEG
, O
mastitis B-NEG
, O
damp-heat B-NEG
jaundice I-NEG
, O
wind-damp B-NEG
impediment O
pain O
, O
bleeding B-NEG
due O
to O
external B-NEG
injury I-NEG
. O

-DOCSTART- O

headache B-NEG

-DOCSTART- O

( O
1 O
) O
cold-type O
hernia B-NEG
; O
periumbilical B-NEG
colic I-NEG
due O
to O
invasion O
of O
cold B-NEG
( O
2 O
) O
testalgia B-NEG
due O
to O
pathogenic O
cold B-NEG

-DOCSTART- O

Analysis O
of O
the O
constituents O
in O
the O
rat O
plasma O
after O
oral O
administration O
of O
Yin O
Chen O
Hao O
Tang O
by O
UPLC/Q-TOF-MS/MS O
. O

-DOCSTART- O

1 O
To O
control O
the O
essence O
; O
2 O
To O
astringe O
the O
intestines B-DNP
and O
stop O
diarrhea B-NEG
; O
3 O
To O
decrease O
urination B-NEU

-DOCSTART- O

redness B-NEG

-DOCSTART- O

Juzentaihoto O
( O
JTT O
) O
is O
a O
well-known O
Japanese O
herbal O
medicine O
, O
which O
has O
been O
reported O
to O
modulate O
immune B-NEU
responses I-NEU
and O
enhance O
antitumor B-POS
immunity I-POS
in O
animal O
models O
. O

However O
, O
it O
is O
not O
clear O
whether O
JTT O
has O
similar O
effects O
on O
humans O
. O

In O
particular O
, O
there O
is O
little O
information O
on O
the O
effects O
of O
JTT O
in O
antigen-specific B-NEU
immunity I-NEU
in O
cancer B-NEG
patients O
. O

Here O
we O
conducted O
a O
randomized O
clinical O
study O
to O
investigate O
whether O
combined O
usage O
of O
JTT O
could O
affect O
antigen-specific B-NEU
immunity I-NEU
and O
clinical O
findings O
in O
advanced O
pancreatic B-NEG
cancer I-NEG
patients O
undergoing O
personalized O
peptide O
vaccination O
( O
PPV O
) O
, O
in O
which O
HLA-matched O
vaccine O
antigens O
were O
selected O
based O
on O
the O
preexisting O
host O
immunity O
. O

Fifty-seven O
patients O
were O
randomly O
assigned O
to O
receive O
PPV O
with O
(n O
= O
28 O
) O
or O
without O
(n O
= O
29 O
) O
JTT O
. O

Unexpectedly O
, O
JTT O
did O
not O
significantly O
affect O
cellular O
or O
humoral O
immune B-NEU
responses I-NEU
specific O
to O
the O
vaccine O
antigens O
, O
which O
were O
determined O
by O
antigen B-NEU
- I-NEU
specific I-NEU
interferon I-NEU
- I-NEU
y I-NEU
secretion I-NEU
in O
T B-DNP
cells I-DNP
and O
antigen B-DNP
- I-DNP
specific I-DNP
IgG I-DNP
titers I-DNP
in O
plasma O
, O
respectively O
. O

Nevertheless O
, O
JTT O
prevented O
deterioration O
of O
patients' O
conditions O
, O
such O
as O
anemia B-NEG
, O
lymphopenia B-NEG
, O
hypoalbuminemia B-NEG
, O
plasma B-DNP
IL-6 I-DNP
elevation O
, O
and O
reduction O
of O
performance O
status O
, O
which O
are O
frequently O
observed O
in O
advanced O
cancers B-NEG
. O

To O
our O
knowledge O
, O
this O
is O
the O
first O
clinical O
study O
that O
examined O
the O
immunological O
and O
clinical O
effects O
of O
JTT O
in O
cancer O
patients O
undergoing O
immunotherapy O
in O
humans O
. O

-DOCSTART- O

Diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
Hemostatic B-DNP
function I-DNP
, O
Others O

-DOCSTART- O

The O
Chinese O
herb O
modified O
Yi O
Guan O
Jian O
( O
mYGJ O
) O
is O
an O
effective O
regimen O
that O
is O
usually O
used O
in O
outpatients O
with O
chronic B-NEG
liver I-NEG
diseases I-NEG
such O
as O
fibrosis B-NEG
and O
cirrhosis B-NEG
. O

However O
, O
the O
mechanism O
for O
the O
action O
of O
mYGJ O
on O
liver B-NEG
fibrosis I-NEG
is O
not O
yet O
clear O
. O

In O
this O
study O
, O
we O
found O
that O
mYGJ O
induced O
hepatic B-DNP
stellate I-DNP
cells I-DNP
( O
HSCs B-DNP
) O
apoptosis O
concomitant O
with O
the O
downregulation O
of O
Bcl-2 B-NEU
expression I-NEU
and O
slight O
elevation O
of O
Bax B-NEU
level I-NEU
. O

Moreover O
, O
the O
reactive B-DNP
oxygen I-DNP
species I-DNP
( O
ROS B-DNP
) O
were O
generated O
in O
the O
early O
stages O
of O
mYGJ-induced O
HSCs O
apoptosis O
to O
facilitate O
calcium O
and O
cytochrome O
c O
release O
from O
the O
mitochondria O
to O
cytosol O
. O

Subsequently O
, O
caspase B-DNP
9 I-DNP
and O
caspase B-DNP
3 I-DNP
were O
activated O
. O

Furthermore O
, O
the O
activation O
of O
ER O
stress-associated O
caspase B-DNP
12 I-DNP
in O
HSCs B-DNP
was O
also O
evaluated O
. O

Together O
, O
we O
report O
the O
first O
evidence-based O
study O
to O
demonstrate O
that O
mYGJ O
decoction O
induces O
HSCs B-DNP
apoptosis O
through O
ROS B-DNP
accumulation O
and O
the O
intrinsic O
apoptosis O
pathway O
. O

These O
findings O
provide O
rationale O
for O
further O
clinical O
investigation O
of O
traditional O
Chinese O
medicine O
recipes O
against O
liver B-NEG
fibrosis I-NEG
. O

-DOCSTART- O

Acute O
Gout B-NEG
Flare O

-DOCSTART- O

nocturnal B-NEU
emission I-NEU
; O
emission B-NEU
; O
spermatorrhea B-NEU
; O
seminal B-NEU
emission I-NEU

-DOCSTART- O

This O
is O
a O
syndrome B-NEG
with I-NEG
numbness I-NEG
and O
a O
pain B-NEG
due O
to O
Wind-Dampness B-NEG
. O

-DOCSTART- O

To O
dispel O
cold B-NEG
, O
eliminate O
damp B-NEG
and O
phlegm B-NEG
, O
and O
to O
arrest O
emesis B-NEG
or O
nausea B-NEG
. O

-DOCSTART- O

Hepatitis B-NEG
B I-NEG
, I-NEG
Chronic I-NEG

-DOCSTART- O

all O
kinds O
of O
disease B-NEG
due O
to O
wind B-NEG

-DOCSTART- O

For O
the O
treatment O
of O
heparin-induced B-NEG
thrombocytopenia I-NEG

-DOCSTART- O

Migraine B-NEG

-DOCSTART- O

To O
quicken O
blood B-DNP
and O
free O
menstruation B-DNP
( O
raw O
) O
, O
transform O
stasis B-NEG
and O
stanch B-POS
bleeding I-POS
( O
scorch-fry O
) O
. O

-DOCSTART- O

pull O
up O
toxicity B-NEG
and O
regenerate O
flesh O

-DOCSTART- O

red-white O
dysentery B-NEG

-DOCSTART- O

Yang O
poison B-NEG
; O
extreme O
heat O
; O
symptoms O
due O
to O
extreme O
heat O

-DOCSTART- O

Multiple B-NEG
Myeloma I-NEG
and O
Plasma B-NEG
Cell I-NEG
Neoplasm I-NEG

-DOCSTART- O

pulmonary B-NEG
carbuncle I-NEG
; O
lung B-NEG
abscess I-NEG

-DOCSTART- O

To O
promote O
blood B-NEU
circulation I-NEU
, O
strengthen O
the O
muscles B-DNP
and O
tendon B-DNP
, O
regulate O
the O
function O
between O
qi O
and O
blood O
. O

-DOCSTART- O

Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Reproductive B-DNP
systems I-DNP
, O
Physical B-DNP
performance B-DNP
and O
fitness B-POS
, O
Quality O
of O
life O
, O
Endocrine B-DNP
system I-DNP
, O
Motivation O
, O
Endurance B-NEU
, O
Memory B-POS
, O
Hemostatic B-DNP
function I-DNP
, O
energy O
supply O
and O
recovery B-POS
, O
Liver B-DNP
health I-DNP
, O
Protective B-NEU
immunity I-NEU
, O
Diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP
, O
Liver B-DNP
, O
Others O
, O
Respiratory B-DNP
systems I-DNP
, O
effort O
, O
Respiratory B-DNP
systems I-DNP
health I-DNP

-DOCSTART- O

A O
symptom O
that O
the O
chest O
is O
heavy O
and O
full O
. O

-DOCSTART- O

Labetuzumab O
is O
a O
humanized O
monoclonal O
antibody O
used O
to O
treat O
cancer O
. O

Retrieved O
from O
http://en.wikipedia.org/wiki/Labetuzumab O

-DOCSTART- O

Treatment O
of O
protracted O
diarrhea B-NEG
due O
to O
hypofunction B-NEG
of O
the O
spleen B-DNP
, O
seminal B-NEU
emission I-NEU
, O
leukorrhagia B-NEG
, O
palpitation B-NEG
, O
insomnia B-NEG
. O

-DOCSTART- O

Treatment O
of O
attack O
of O
damp-heat B-NEU
manifested O
by O
stuffiness B-NEG
and O
fullness B-NEG
sensation O
in O
the O
abdomen O
, O
or O
causing O
acute O
dysentery B-NEG
of O
jaundice B-NEG
, O
high O
fever B-NEG
accompained O
by O
impairment O
of O
conciousness O
, O
fidgetness B-NEG
and O
insomnia B-NEG
due O
to O
exuberant O
fire O
, O
spitting B-NEG
of I-NEG
blood I-NEG
and O
epistaxis B-NEG
caused O
by O
heat B-NEU
in O
the O
blood B-DNP
, O
inflammation B-NEG
of O
the O
eye O
, O
acid O
regurgitation O
, O
toothache B-NEG
, O
diabetes B-NEG
, O
carbuncles B-NEG
and O
sores B-NEG
, O
external O
use O
for O
eczema B-NEG
and O
other O
skin B-NEG
diseases I-NEG
with O
exudation B-NEG
, O
purulent B-NEG
discharge I-NEG
from O
the O
ear O
. O

-DOCSTART- O

stroke B-NEG
; O
sudden B-NEG
wind-stroke I-NEG
a O
sudden B-NEG
and I-NEG
severe I-NEG
attack I-NEG
, O
as O
of O
apoplexy B-NEG

-DOCSTART- O

Cholestyramine O
binds O
bile O
in O
the O
gastrointestinal O
tract O
to O
prevent O
its O
reabsorption O
. O

-DOCSTART- O

stop O
tearing O

-DOCSTART- O

warm O
large O
intestine B-DNP

-DOCSTART- O

phlegmy B-NEG
fire O
a O
morbid O
condition O
produced O
by O
long-standing O
depression B-NEG
of O
Gi O
which O
turns O
into O
fire O
and O
changes O
the O
body O
fluid O
into O
phlegm B-NEG
, O
usually O
causing B-NEG
mental I-NEG
disturbances O
such O
as O
hysteria B-NEG
, O
mania B-NEG
. O

-DOCSTART- O

dysenteric B-NEG
disorder I-NEG
; O
dysentery B-NEG

-DOCSTART- O

Post-operative B-NEG
Pain I-NEG

-DOCSTART- O

To O
relieve O
dyspnea B-NEG
and O
cough B-NEG
by O
eliminating O
cold-phlegm B-NEG
, O
to O
reduce O
modulation O
, O
and O
to O
relieve O
pain B-NEG
by O
removing O
the O
obstruction O
of O
collateral O
. O

-DOCSTART- O

Strength O
and O
power O
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Digestion B-NEU
, O
Liver B-DNP
, O
Lipid O
profile O
, O
Quality O
of O
life O
, O
absorption O
, O
Neurological B-DNP
systems I-DNP
health I-DNP
, O
Overall O
CVD O
, O
Liver B-DNP
health I-DNP
, O
Diet related O
cardiovascular B-NEG
disease I-NEG
, O
Inflammation B-NEG
, O
Other O
system O
health O
, O
Others O
, O
Neurological B-DNP
systems I-DNP
, O
Physical B-DNP
performance I-DNP
and O
fitness O
, O
Protective O
immunity B-NEU
, O
Hemostatic B-NEU
function I-NEU
, O
motility O

-DOCSTART- O

1 O
To O
clear O
the O
lungs B-DNP
and O
tonify O
yin O
; O
2 O
To O
strengthen O
the O
stomach B-DNP
and O
promote O
the O
production B-NEU
of I-NEU
body I-NEU
fluids I-NEU

-DOCSTART- O

Ritonavir O
inhibits O
the O
HIV B-NEG
viral O
proteinase O
enzyme O
which O
prevents O
cleavage O
of O
the O
gag-pol O
polyprotein O
, O
resulting O
in O
noninfectious O
, O
immature O
viral O
particles O
. O

-DOCSTART- O

epidemic B-NEG
smallpox I-NEG

-DOCSTART- O

The O
symptomatic O
relief O
of O
cough B-NEG
. O

-DOCSTART- O

Progestins O
diffuse O
freely O
into O
target O
cells O
and O
bind O
to O
the O
progesterone O
receptor O
. O

Once O
bound O
to O
the O
receptor O
, O
progestins O
slow O
the O
frequency O
of O
release O
of O
gonadotropin O
releasing O
hormone O
( O
GnRH O
) O
from O
the O
hypothalamus O
and O
blunt O
the O
pre-ovulatory O
LH O
surge O
. O

Ethinyl O
estradiol O
is O
a O
synthetic O
derivative O
of O
the O
natural O
estrogen O
estradiol O
. O

Estrogens O
increase O
the O
hepatic B-NEU
synthesis I-NEU
of I-NEU
sex I-NEU
hormone I-NEU
binding O
globulin O
, O
thyroid-binding O
globulin O
, O
and O
other O
serum B-DNP
proteins I-DNP
and O
suppress O
follicle-stimulating B-DNP
hormone I-DNP
from O
the O
anterior O
pituitary O
. O

-DOCSTART- O

dispel O
wind-damp B-NEG

-DOCSTART- O

harmonize O
blood B-NEU

-DOCSTART- O

The O
so O
called O
renin-angiotensin B-DNP
system I-DNP
( O
RAS B-DNP
) O
is O
an O
important O
regulator O
of O
blood B-NEU
pressure I-NEU
and O
has O
already O
been O
successfully O
targeted O
by O
three O
major O
classes O
of O
antihypertensive O
drugs O
: O
by O
ACE O
inhibitors O
, O
by O
ARBs O
and O
by O
renin O
inhibitors O
. O

-DOCSTART- O

( O
1 O
) O
hematochezia B-NEG
( O
2 O
) O
viginal B-NEG
bleeding I-NEG

-DOCSTART- O

dizziness B-NEG
and O
vertigo B-NEG

-DOCSTART- O

Roundworm B-NEG

-DOCSTART- O

edema B-NEG
, O
pathogenesis O
of O
which O
is O
associated O
with O
dysfunction B-NEG
of I-NEG
the I-NEG
lung I-NEG
, I-NEG
spleen I-NEG
and I-NEG
kidney I-NEG
. O

-DOCSTART- O

harmonize O
blood B-DNP
vessel I-DNP

-DOCSTART- O

Sermorelin O
binds O
to O
the O
growth O
hormone O
releasing O
hormone O
receptor O
and O
mimics O
native O
GRF O
in O
its O
ability O
to O
stimulate B-NEU
growth I-NEU
hormone I-NEU
secretion I-NEU
. O

-DOCSTART- O

pyogenic B-NEG
infections I-NEG
due O
to O
furuncle B-NEG

-DOCSTART- O

the O
four O
limbs O
are O
swollen B-NEG
and O
they O
feel O
painful O

-DOCSTART- O

We O
reported O
previously O
that O
cholesterol O
feeding O
induced O
an O
increase O
in O
hepatic B-NEU
secretion I-NEU
of O
VLDL B-DNP
and O
a O
decrease O
in O
that O
of O
LDL B-DNP
, O
especially O
LDL-apo B-DNP
B100 I-DNP
, O
using O
monkey O
liver O
perfusion O
. O

In O
the O
present O
study O
we O
conducted O
rat O
liver O
perfusion O
using O
the O
HMG O
Co O
A O
reductase O
inhibitor O
( O
CB-514 O
) O
and O
Kampo O
medicine O
( O
Daisaikoto O
) O
to O
elucidate O
the O
mechanism O
of O
the O
effect O
of O
dietary O
cholesterol O
on O
hepatic B-NEU
lipoprotein I-NEU
and O
apolipoprotein B-NEU
synthesis I-NEU
. O

Although O
the O
secretion B-NEU
of I-NEU
VLDL I-NEU
was O
increased O
by O
cholesterol O
feeding O
, O
that O
of O
LDL B-DNP
and O
especially O
of O
apo B-DNP
B100 I-DNP
of I-DNP
LDL I-DNP
were O
markedly O
decreased O
, O
and O
apo B-DNP
E I-DNP
of I-DNP
the I-DNP
LDL I-DNP
was O
increased O
as O
observed O
in O
the O
monkey O
liver O
perfusion O
experiments O
. O

The O
effect O
of O
CB-514 O
was O
clearly O
different O
from O
the O
effect O
of O
dietary O
cholesterol B-DNP
in O
spite O
of O
the O
suppression O
of O
hepatic O
cholesterogenesis O
which O
was O
comparable O
to O
that O
induced O
by O
cholesterol O
feeding O
, O
suggesting O
that O
the O
decrease O
in O
secretion B-NEU
of I-NEU
LDL-apo I-NEU
B100 I-NEU
induced O
by O
the O
dietary O
cholesterol O
is O
not O
due O
to O
suppressed O
cholesterogenesis O
. O

Daisaikoto O
, O
which O
was O
added O
to O
the O
diet O
together O
with O
cholesterol O
, O
diminished O
the O
effects O
of O
dietary O
cholesterol O
on O
the O
plasma B-NEU
and I-NEU
hepatic I-NEU
cholesterol I-NEU
levels I-NEU
. O

When O
the O
liver O
treated O
with O
Daisaikoto O
was O
perfused O
, O
the O
effect O
of O
dietary O
cholesterol O
on O
the O
production B-NEU
of I-NEU
lipoprotein I-NEU
and I-NEU
apolipoprotein I-NEU
was O
markedly O
diminished O
. O

This O
evidence O
indicates O
that O
the O
decrease O
in O
LDL-apo B-DNP
B100 I-DNP
and O
the O
increase O
in O
apo B-DNP
E I-DNP
were O
mediated O
by O
the O
hepatic B-NEU
cholesterol I-NEU
level I-NEU
. O

-DOCSTART- O

To O
kill O
roundworms B-NEG
; O

To O
kill O
worms B-NEG
; O

To O
move O
qi O
; O

To O
stop O
pain B-NEG

-DOCSTART- O

The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
effects O
of O
the O
water O
extract O
of O
Samultang O
( O
SMT O
) O
, O
a O
Chinese O
herb O
, O
on O
apoptotic O
cell B-NEU
death I-NEU
by O
H(2)O(2)-induced O
oxidative O
stress O
in O
SK-N-MC O
cells O
. O

A O
nuclear O
fragmentation O
was O
observed O
via O
fluorescence O
imaging O
12 O
h O
after O
exposure O
to O
30 O
microM O
H(2)O(2 O
) O
and O
DNA O
laddering O
was O
detected O
via O
agarose O
electrophoresis O
gel O
. O

In O
addition O
, O
increases O
in O
sub-G1 O
phase O
and O
cleavage O
of O
the O
PARP O
protein O
were O
observed O
. O

However O
, O
treatment O
with O
SMT O
for O
2 O
h O
prior O
to O
H(2)O(2 O
) O
exposure O
significantly O
reduced O
apoptotic O
cell B-NEU
death I-NEU
induced O
by O
incubation O
with O
30 O
microM O
H(2)O(2 O
) O
in O
SK-N-MC O
cells O
. O

Pre-incubation O
with O
water O
extract O
of O
SMT O
for O
2 O
h O
prevented O
the O
H(2)O(2)-induced O
decrease O
in O
mitochondrial O
transmembrane O
potential O
. O

SMT O
also O
attenuated O
the O
increase O
in O
caspase-3 B-NEU
activity I-NEU
and O
the O
breakdown O
of O
PARP B-DNP
protein I-DNP
caused O
by O
H(2)O(2)-induced O
oxidative O
stress O
. O

These O
results O
suggest O
that O
the O
water O
extract O
of O
SMT O
provides O
inhibition O
of O
apoptotic O
cell B-NEU
death I-NEU
against O
oxidative O
injury O
in O
SK-N-MC O
cells O
. O

-DOCSTART- O

Ovarian B-NEG
Hyperstimulation I-NEG
Syndrome I-NEG

-DOCSTART- O

phlegm B-NEG
syndrome I-NEG
induced O
by O
fright O

-DOCSTART- O

hypochondriac B-NEG
pain I-NEG

-DOCSTART- O

To O
provide O
some O
insights O
how O
herbal O
medicines O
affect O
deoxyribonucleic B-NEU
acid I-NEU
( I-NEU
DNA I-NEU
) I-NEU
synthesis I-NEU
in O
the O
uterus O
, O
the O
DNA B-NEU
polymerase I-NEU
activities I-NEU
( O
alpha O
and O
beta O
) O
in O
uterine O
samples O
taken O
from O
rats O
were O
measured O
. O

DNA B-NEU
polymerase I-NEU
alpha I-NEU
activity I-NEU
with O
respect O
to O
DNA O
content O
revealed O
alpha O
cyclic O
change O
with O
the O
highest O
level O
on O
proestrus O
, O
while O
DNA B-NEU
polymerase I-NEU
beta I-NEU
activity I-NEU
showed O
no O
significant O
changes O
during O
the O
estrous O
cycle O
. O

The O
increased O
period O
of O
the O
activity O
coincided O
with O
that O
of O
17 B-DNP
beta-estradiol I-DNP
( O
E2 B-DNP
) O
but O
not O
progesterone B-DNP
( O
P4 B-DNP
) O
in O
the O
blood O
. O

Injection O
of O
10 O
IU O
pregnant O
mare O
serum O
gonadotropin O
( O
PMS O
) O
on O
day O
27 O
of O
age O
gradually O
increased O
DNA B-NEU
polymerase I-NEU
alpha I-NEU
activity I-NEU
in O
uteri O
, O
while O
concomitant O
treatment O
with O
PMS O
and O
200 O
micrograms O
Tokishakuyakusan O
( O
TS O
) O
, O
Keishibukuryogan O
( O
KB O
) O
or O
Unkeito O
( O
UT O
) O
suppressed O
the O
enzyme B-NEU
activity I-NEU
, O
with O
a O
most O
remarkable O
effect O
of O
KB O
. O

These O
results O
suggest O
that O
TS O
, O
KB O
or O
UT O
suppresses O
in O
vivo O
DNA B-NEU
polymerase I-NEU
alpha I-NEU
activity I-NEU
induced O
by O
PMS O
in O
the O
rat O
uterus O
. O

-DOCSTART- O

105AD7 O
vaccine O
is O
a O
human O
anti-idiotype O
which O
mimics O
the O
antigen B-DNP
791Tgp72 I-DNP
. O

The O
mechanism O
of O
action O
of O
the O
vaccine O
has O
recently O
been O
clarified O
. O

The O
anti-idiotype O
is O
rapidly O
internalized O
on O
antigen O
presenting O
cells O
by O
Fc O
mediated O
endocytosis O
as O
both O
Fab O
and O
Ab O
complexed O
to O
alum O
are O
processed O
1000 O
fold O
less O
efficiently O
than O
whole O
Ab O
. O

Sequencing O
of O
the O
Ab O
have O
revealed O
that O
the O
CDR-H3 B-DNP
is O
hypermutated O
and O
contains O
HLA B-DNP
A1 I-DNP
, I-DNP
A3 I-DNP
and I-DNP
A24 I-DNP
, O
and O
HLA-DR1 B-DNP
, I-DNP
3 I-DNP
and I-DNP
7 I-DNP
MHC I-DNP
binding O
motifs O
. O

105AD7 O
is O
an O
antibody-based O
vaccine O
that O
mimics O
a O
target O
( O
CD55 B-DNP
) O
which O
is O
over-expressed O
in O
numerous O
cancers B-NEG
including O
those O
of O
the O
prostate B-DNP
, O
colon B-DNP
and O
pancreas B-DNP
. O

-DOCSTART- O

To O
relieve O
cough B-NEG
and O
dyspnea B-NEG
, O
and O
eliminate O
retained O
phlegm B-NEG
. O

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Woman O
, O
Eye B-DNP
, O
Mood O
, O
Physical B-DNP
performance I-DNP
and O
fitness B-POS
, O
Quality O
of O
life O
, O
Eye B-DNP
health I-DNP
, O
Dermatological B-DNP
systems I-DNP
health I-DNP
, O
energy O
supply O
and O
recovery B-POS
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP
, O
General O
woman O
, O
General B-DNP
skin I-DNP
health I-DNP
, O
Others O
, O
Protective B-NEU
immunity I-NEU
, O
Intelligence B-POS
, O
Endurance B-NEU

-DOCSTART- O

This O
is O
a O
syndrome O
with O
felling O
of O
cold B-NEG
and O
a O
pain B-NEG
in O
the O
lower O
abdomen O
. O

-DOCSTART- O

general O
swelling B-NEG
and O
small O
amount O
urine B-DNP

-DOCSTART- O

bloodshot B-NEG
eyes I-NEG
; O
congestion B-NEG
of O
the O
eye O
; O
red B-NEG
eyes I-NEG
; O
redness B-NEG
of I-NEG
the I-NEG
eye I-NEG

-DOCSTART- O

relieve O
pain B-NEG

-DOCSTART- O

For O
appendicitis B-NEG
, O
used O
together O
with O
same O
dose O
of O
pills O
of O
Radix O
et O
Rhizoma O
Rhei O
and O
Rhizoma O
Coptidis O
, O
or O
mixed O
with O
same O
dose O
of O
Cinnabaris O
, O
applying O
on O
point O
Lanwei O
( O
Extra33 O
) O
. O

-DOCSTART- O

Repeated O
administration O
of O
Yokukansan O
inhibits O
DOI-induced O
head-twitch O
response O
and O
decreases O
expression O
of O
5-hydroxytryptamine B-DNP
( I-DNP
5-HT)2A I-DNP
receptors I-DNP
in O
the O
prefrontal O
cortex O
. O

-DOCSTART- O

1 O
Since O
the O
prescription O
possesses O
a O
hemostatic O
action O
, O
it O
is O
also O
indicated O
for O
incised B-NEG
wounds I-NEG
with O
hemorrhage B-NEG
( O
topical O
use O
) O
. O
2 O
Applicable O
to O
cases O
of O
angina B-NEG
pectoris I-NEG
which O
are O
attributive O
to O
retention O
of O
blood B-NEG
stasis I-NEG
. O
3 O
Also O
applicable O
orally O
or O
topi O

-DOCSTART- O

To O
replenish O
the O
liver B-DNP
and O
kidney B-DNP
, O
improve O
eyesight B-POS
and O
promote O
the O
growth B-POS
of I-POS
black I-POS
hair I-POS
. O

-DOCSTART- O

Gastric B-NEG
Varices I-NEG

-DOCSTART- O

To O
open O
orifices O
and O
arouse O
spirit O
, O
break O
phlegm B-NEG
and O
repel O
foulness B-NEG
, O
move O
qi O
and O
quicken O
blood B-DNP
, O
relieve O
pain B-NEG
. O

-DOCSTART- O

Second-degree B-NEG
Burn I-NEG

-DOCSTART- O

For O
relieving O
exterior B-NEG
syndrome I-NEG

-DOCSTART- O

new O
and O
old O
cough B-NEG

-DOCSTART- O

a O
symptom O
of O
pruritis B-NEG
due O
to O
smallpox B-NEG

-DOCSTART- O

Qi O
vacuity O
, O
yin O
depletion O
and O
effulgent O
fire O
, O
cough B-NEG
and O
asthma B-NEG
with O
phlegm-blood B-NEG
, O
vacuity O
heat B-NEG
and O
vexation O
fatigue B-NEG
, O
diabetes B-NEG
mellitus I-NEG
due O
to O
internal O
heat B-NEG
, O
thirst B-NEU
with O
dry B-NEG
throat I-NEG
. O

-DOCSTART- O

all O
kinds O
of O
pain B-NEG
due O
to O
disorder O
of O
Gi O

-DOCSTART- O

Treatment O
of O
wind-heat B-NEU
type O
common O
cold B-NEG
, O
headache B-NEG
and O
dizziness B-NEG
, O
inflammation B-NEG
of O
the O
eye O
, O
blurred O
vision O
. O

-DOCSTART- O

Hypoglycemia B-NEG

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Digestion B-NEU
, O
absorption B-NEU
, O
Lipid O
profile O
, O
motility B-NEU
, O
Evacuation B-NEU

-DOCSTART- O

disperse O
carbuncle B-NEG
swelling B-NEG

-DOCSTART- O

warm O
the O
stomach B-DNP

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Protective B-NEU
immunity I-NEU
, O
Others O

-DOCSTART- O

To O
dissipate O
wind-cold B-NEG
, O
quicken O
network O
vessels B-DNP
and O
relieve O
pain B-NEG
. O

-DOCSTART- O

As O
an O
anthelmintic O
for O
tapeworm O
and O
hookworm O
, O
more O
effective O
than O
that O
of O
tetrachloroethylene O
. O

-DOCSTART- O

brighten O
the O
eyes O

-DOCSTART- O

To O
remove O
damp-heat B-NEU
, O
quench O
fire O
and O
counteract O
toxicity B-NEG
. O

-DOCSTART- O

red B-NEG
face I-NEG

-DOCSTART- O

The O
herbal O
medicine O
Tokishakuyakusan O
increases O
fetal O
blood B-NEU
glucose I-NEU
concentrations I-NEU
and O
growth B-NEU
hormone I-NEU
levels I-NEU
and O
improves O
intrauterine B-NEG
growth I-NEG
retardation I-NEG
induced O
by O
N(omega)-nitro-L-arginine O
methyl O
ester O
. O

-DOCSTART- O

astringe O
and O
stop O
bleeding B-NEG

-DOCSTART- O

[Conservative O
treatment O
of O
benign O
prostatic O
hypertrophy O
- O
clinical O
effects O
of O
increased O
administration O
of O
Hachimijiogan O
and O
the O
relation O
between O
these O
effects O
and O
the O
Sho O
of O
Chinese O
medicine] O
. O

-DOCSTART- O

having O
a O
yellow B-NEG
or I-NEG
reddish I-NEG
urine I-NEG
due O
to O
blocking O
the O
circulation B-DNP
of O
bile O
by O
epidemic O
toxin O
, O
fail O
to O
control O
food O
, O
and O
damp-heat B-NEG
and O
cold-damp B-NEG
blocked O
in O
the O
middle O
heater O

-DOCSTART- O

Follitropin O
alpha O
is O
a O
recombinant O
form O
of O
endogenous O
follicle O
stimulating O
hormone O
( O
FSH O
) O
. O

FSH O
binds O
to O
the O
follicle O
stimulating O
hormone O
receptor O
which O
is O
a O
G-coupled O
transmembrane O
receptor O
. O

Binding O
of O
the O
FSH O
to O
its O
receptor O
seems O
to O
induce O
phosphorylation B-DNP
and O
activation B-NEU
of I-NEU
the I-NEU
PI3K I-NEU
( O
Phosphatidylinositol-3-kinase O
) O
and O
Akt O
signaling O
pathway O
, O
which O
is O
known O
to O
regulate O
many O
other O
metabolic O
and O
related O
survival/maturation O
functions O
in O
cells O
. O

-DOCSTART- O

To O
tonify O
the O
liver B-DNP
and O
the O
kidney B-DNP
, O
to O
strengthen O
the O
tendons B-DNP
and O
bones B-DNP
, O
and O
to O
prevent O
miscarrige B-NEG
. O

-DOCSTART- O

invigorate O
blood B-NEU
and O
resolve O
stasis B-NEG

-DOCSTART- O

When O
administered O
, O
G17DT O
induces O
an O
immune B-NEU
response I-NEU
producing O
antibodies O
which O
bind O
with O
the O
peptide O
and O
also O
cross-react O
and O
neutralise O
gastrin B-DNP
17 I-DNP
thus O
inhibiting O
the O
growth B-NEU
of I-NEU
cancers I-NEU
and O
metastasis B-NEU
. O

In O
addition O
the O
product O
neutralizes O
glycine-extended O
gastrin O
17 O
which O
is O
also O
a O
stomach O
and O
pancreatic O
cancer O
growth O
factor O
. O

-DOCSTART- O

( O
1 O
) O
morbid B-NEG
leukorrhea I-NEG
; O
( O
2 O
) O
gynecological B-NEG
diseases(in I-NEG
a O
broad O
sense O
) O

-DOCSTART- O

Diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
Hemostatic B-DNP
function I-DNP
, O
Overall O
CVD B-NEG
, O
Other O
system B-DNP
health I-DNP
, O
Others O

-DOCSTART- O

carbuncle B-NEG
and O
cellulitis B-NEG

-DOCSTART- O

sore B-NEG
throat I-NEG
; O
swollen B-NEG
and I-NEG
pailful I-NEG
throat I-NEG

-DOCSTART- O

Dermatitis B-NEG
, I-NEG
Atopic I-NEG

-DOCSTART- O

mental B-NEG
confusion I-NEG

-DOCSTART- O

stranguria B-NEG
due O
to O
urinary O
stone O
; O
dysuria B-NEG
caused O
by O
urinary O
stone O
; O
stranguria B-NEG
due O
to O
urolithiasis B-NEG
; O
stony B-NEG
dysuria I-NEG
; O
dysuria B-NEG
caused O
by O
calculi O

-DOCSTART- O

Gramicidin O
D O
binds O
and O
inserts O
itself O
into O
bacterial B-DNP
membranes I-DNP
and O
results O
in O
membrane B-NEG
disruption I-NEG
and O
permeabilization B-NEG
, O
which O
leads O
to O
cell B-NEU
death I-NEU
. O

Polymyxin O
B O
sulfate O
interacts O
with O
the O
lipopolysaccharide O
of O
the O
cytoplasmic O
outer O
membrane O
of O
Gram-negative O
bacteria O
, O
altering O
membrane O
permeability O
and O
causing O
cell B-NEU
death I-NEU
. O

Neomycin O
is O
a O
bactericidal O
aminoglycoside O
antibiotic O
that O
binds O
to O
the O
30S O
ribosome O
of O
susceptible O
organisms O
. O

Binding O
interferes O
with O
mRNA B-NEU
binding I-NEU
and O
acceptor O
tRNA O
sites O
and O
results O
in O
the O
production O
of O
non-functional O
or O
toxic B-DNP
peptides I-DNP
. O

-DOCSTART- O

hematemesis B-NEG
; O
blood B-NEG
vomiting I-NEG
; O
spitting B-NEG
blood I-NEG
; O
blood B-NEG
vomiting I-NEG

-DOCSTART- O

1 O
Inhibiting O
experimental O
arthritis B-NEG
in O
mice O
and O
decreasing O
capillary B-NEU
permeability I-NEU
. O

2 O
. O
Anti-allergric B-NEU
. O

3 O
. O
Inducing O
transient O
hypotensive B-NEG
effect I-NEG
. O

-DOCSTART- O

furuncle B-NEG
; O
boil B-NEG

-DOCSTART- O

The O
bactericidal O
action O
of O
lomefloxacin O
results O
from O
interference O
with O
the O
activity B-NEG
of I-NEG
the I-NEG
bacterial I-NEG
enzymes I-NEG
DNA I-NEG
gyrase I-NEG
and O
topoisomerase B-DNP
IV I-DNP
, O
which O
are O
needed O
for O
the O
transcription O
and O
replication O
of O
bacterial O
DNA O
, O
as O
a O
result O
of O
inhibition O
of O
DNA B-NEU
replication I-NEU
and I-NEU
transcription I-NEU
. O

Furosemide O
blocks O
the O
Na-K-Cl B-DNP
cotransporter I-DNP
( O
NKCC B-DNP
) O
in O
the O
luminal O
membrane O
of O
the O
thick O
ascending O
limb O
of O
the O
loop O
of O
Henle O
in O
the O
kidney O
, O
by O
binding O
to O
the O
Cl-binding O
site O
located O
in O
the O
cotransporter's O
transmembrane O
domain O
, O
thereby O
inhibiting O
reabsorption B-NEU
of I-NEU
sodium I-NEU
, O
chloride B-DNP
, O
potassium B-DNP
ions I-DNP
and O
water O
. O

This O
agent O
reduces O
plasma B-DNP
and O
extracellular B-NEU
fluid I-NEU
volume I-NEU
resulting O
in O
decreased O
blood B-NEU
pressure I-NEU
and O
cardiac B-NEU
output I-NEU
. O

-DOCSTART- O

A O
traditional O
Japanese O
herbal O
( O
Kampo O
) O
medicine O
, O
Hochuekkito O
( O
Bu-Zhong-Yi-Qi-Tang O
in O
Chinese O
, O
TJ-41 O
) O
is O
a O
well-known O
Kampo O
formula O
, O
and O
has O
been O
found O
to O
enhance O
antigen-specific B-NEU
antibody I-NEU
response I-NEU
in O
not O
only O
local O
mucosal O
immune B-DNP
system I-DNP
in O
upper O
respiratory O
tract O
, O
but O
also O
systemic O
immune B-DNP
system I-DNP
through O
upper O
respiratory O
mucosal O
immune O
system O
. O

Although O
this O
immunopharmacological O
effect O
has O
been O
proposed O
to O
express O
by O
modulation O
of O
intestinal O
immune B-DNP
system I-DNP
including O
Peyer's O
patches O
and O
intestinal O
epithelial B-DNP
cells I-DNP
, O
active O
ingredients O
are O
not O
known O
. O

TJ-41 O
directly O
affected O
the O
production O
of O
bone B-DNP
marrow I-DNP
cell I-DNP
- O
proliferative O
growth B-DNP
factors I-DNP
from O
murine O
Peyer's O
patch O
immunocompetent O
cells O
in O
vitro O
. O

Among O
low O
molecular O
, O
intermediate O
size O
and O
macromolecular O
weight O
fractions O
prepared O
from O
TJ-41 O
, O
only O
fraction O
containing O
macromolecular O
weight O
ingredients O
showed O
Peyer's O
patch O
- O
mediated O
bone B-DNP
marrow I-DNP
cell I-DNP
- O
proliferation O
enhancing O
activity O
. O

Anion-exchange O
chromatography O
and O
gel O
filtration O
gave O
17 O
subfractions O
comprising O
polysaccharides O
and O
lignins O
from O
the O
macromolecular O
weight O
fraction O
of O
TJ-41 O
, O
and O
some O
of O
the O
subfractions O
showed O
significant O
enhancing O
activities O
having O
different O
degrees O
. O

Some O
of O
the O
subfractions O
also O
expressed O
stimulating O
activity O
on O
G-CSF B-DNP
- O
production O
from O
colonic O
epithelial O
cells O
, O
and O
statistically O
significant O
positive O
correlation O
was O
observed O
among O
enhancing O
activities O
of O
the O
subfractions O
against O
Peyer's O
patch O
immunocompetent B-DNP
cells I-DNP
and O
epithelial B-DNP
cells I-DNP
. O

Among O
the O
fractions O
from O
TJ-41 O
oral O
administration O
of O
macromolecular O
weight O
ingredient O
fraction O
to O
mice O
succeeded O
to O
enhance O
antigen-specific B-NEU
antibody I-NEU
response I-NEU
in O
systemic O
immune B-DNP
system I-DNP
through O
upper O
respiratory O
mucosal O
immune O
system O
, O
but O
all O
the O
separated O
fractions O
failed O
to O
enhance O
the O
in O
vivo O
antibody B-NEU
response I-NEU
in O
upper O
respiratory O
tract O
. O

-DOCSTART- O

Treatment O
of O
rheumatic B-NEG
or I-NEG
rheumatoid I-NEG
arthrits I-NEG
with O
muscular B-NEG
contracture I-NEG
and O
severe O
joint B-NEG
pain I-NEG
, O
fever B-NEG
recurring O
daily O
in O
the O
afternoon O
, O
fever B-NEG
in I-NEG
infants I-NEG
with O
malnutrition B-NEG
. O

-DOCSTART- O

Strength B-POS
and O
power B-POS
, O
Physical B-DNP
performance I-DNP
and O
fitness B-POS

-DOCSTART- O

To O
clear O
away O
heat B-NEU
and O
toxic B-NEG
materials I-NEG
. O

-DOCSTART- O

Infant B-NEG
, I-NEG
Newborn I-NEG
, I-NEG
Diseases I-NEG

-DOCSTART- O

epigastric O
twisting O
pain B-NEG
. O

-DOCSTART- O

To O
dispel O
wind-damp B-NEG
, O
quicken O
blood B-DNP
and O
relieve O
pain B-NEG
, O
resolve O
toxin B-NEG
. O

-DOCSTART- O

prolapse B-NEG
of I-NEG
uterus I-NEG

-DOCSTART- O

invigorate O
the O
network B-DNP
vessels I-DNP

-DOCSTART- O

Treatment O
of O
consumptive B-NEG
diseases I-NEG
, O
impotence B-NEG
, O
cold B-NEG
sperm I-NEG
, O
lassitude B-NEG
in O
the O
loins O
and O
legs O
due O
to O
deficiency O
of O
the O
kidney-yang O
, O
etc O
. O

-DOCSTART- O

Exposure B-NEG
to I-NEG
Hepatitis I-NEG
B I-NEG
Virus I-NEG

-DOCSTART- O

Hypertension B-NEG
. O

-DOCSTART- O

Injury B-NEG
of I-NEG
Bladder I-NEG

-DOCSTART- O

To O
remove O
heat B-NEU
and O
counteract O
toxicity B-NEG
, O
to O
expel O
intestinal B-NEG
worms I-NEG
, O
stanch O
bleeding B-NEG
. O

-DOCSTART- O

diabetes B-NEG
; O
wasting(emaciation B-NEG
) O
and O
thirsting B-NEG
syndrome I-NEG

-DOCSTART- O

retention O
of O
undigested O
food O
; O
dyspepsia O

-DOCSTART- O

This O
is O
kinds O
of O
consciousness B-NEG
disorder I-NEG
with O
a O
light O
stupor O
. O
It O
is O
sleeping O
at O
nights O
and O
days O
, O
and O
responding O
with O
opening O
an O
eye O
. O
It O
is O
cause O
by O
palsy B-NEG
. O

-DOCSTART- O

Spontaneous O
external O
bleeding B-NEG
, O
hematochezia B-NEG
, O
headache B-NEG
, O
dizziness B-NEG
and O
dim B-NEG
vision I-NEG
, O
red B-NEG
eyes I-NEG
, O
night B-NEG
blindness I-NEG
, O
diabetes B-NEG
mellitus I-NEG
, O
fecal B-NEG
stoppage I-NEG
, O
hemorrhoids B-NEG
. O

-DOCSTART- O

Chloramphenicol O
reversibly O
binds O
to O
the O
L16 O
protein O
of O
the O
50S O
subunit O
of O
bacterial O
ribosomes O
, O
thus O
inhibits O
protein B-NEU
synthesis I-NEU
. O

Desoxyribonuclease O
is O
a O
biosynthetic O
form O
of O
human O
DNase O
I, O
which O
is O
involved O
in O
endonucleolytic O
cleavage O
of O
extracellular O
DNA O
to O
5-phosphodinucleotide O
and O
5-phosphooligonucleotide O
end O
products O
. O

Fibrinolysin O
attacks O
and O
inactivates O
fibrin B-DNP
molecules I-DNP
occurring O
in O
undesirable O
exudates O
on O
the O
surface O
of O
the O
human O
body O
and O
on O
human O
mucosa O
. O

-DOCSTART- O

SP-01A O
is O
an O
HIV B-NEG
oral O
entry O
inhibitor O
drug O
. O
In O
order O
for O
viruses B-NEG
to O
reproduce O
, O
they O
must O
infect O
or O
hi-jack O
a O
cell O
, O
and O
use O
it O
to O
make O
new O
viruses O
. O
Just O
as O
your O
body O
is O
constantly O
making O
new O
skin B-DNP
cells I-DNP
, O
or O
new O
blood B-DNP
cells I-DNP
, O
each O
cell O
often O
makes O
new O
proteins O
in O
order O
to O
stay O
alive O
and O
to O
reproduce O
itself O
. O
Viruses O
hide O
their O
own O
DNA O
in O
the O
DNA O
of O
the O
cell O
, O
and O
then O
, O
when O
the O
cell O
tries O
to O
make O
new O
proteins O
, O
it O
accidentally O
makes O
new O
viruses O
as O
well O
. O
HIV B-NEG
mostly O
infects O
cells O
in O
the O
immune B-NEU
system I-NEU
. O

-DOCSTART- O

Treatment O
of O
sore B-NEG
throat I-NEG
and O
hoarseness B-NEG
of I-NEG
voice I-NEG
, O
cough B-NEG
with O
yellow O
sticky O
sputum B-NEG
, O
dysuria B-NEG
, O
external O
use O
for O
pemphigus B-NEG
and O
eczema B-NEG
. O

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Digestion B-NEU
, O
absorption B-NEU
, O
motility B-NEU
, O
Evacuation B-NEU
, O
Protective O
immunity B-NEU

-DOCSTART- O

nfantile O
malnutrition B-NEG
with O
diarrhea B-NEG

-DOCSTART- O

deficiency O
of O
both O
Gi O
( O
vital O
energy O
) O
and O
blood B-DNP

-DOCSTART- O

To O
clear O
heat B-NEG
and O
resolve O
toxin O
, O
disinhibit O
water O
and O
disperse O
edema B-NEG
. O

-DOCSTART- O

For O
tonifying O
blood B-DNP

-DOCSTART- O

T'aeyang B-NEG
meridian I-NEG
affected O
by O
the O
wind B-NEG
; O

invasion B-NEG
of I-NEG
wind I-NEG
pathogen I-NEG
in O
T'aeyang B-NEG
meridian I-NEG

-DOCSTART- O

Esophageal B-NEG
Bleeding I-NEG

-DOCSTART- O

Diet O
related O
cardiovascular B-NEG
disease I-NEG
, O
Lipid B-NEU
profile I-NEU

-DOCSTART- O

This O
is O
bleeding B-NEG
due O
to O
an O
external B-NEG
wound I-NEG
. O

-DOCSTART- O

freckles B-NEG
on O
face O

-DOCSTART- O

For O
dispelling O
wind-dampness B-NEG
and O
dispersing O
coldness B-NEG
. O

-DOCSTART- O

Schizophrenia B-NEG

-DOCSTART- O

nourish O
the O
liver B-DNP
and O
kidney B-DNP

-DOCSTART- O

night B-NEG
blindness I-NEG
. O
Visual B-NEG
disorder I-NEG
at O
night O
. O

-DOCSTART- O

insulin O
sensitivity O
and O
diabetes B-NEG
risk O
, O
Body B-NEU
weight I-NEU
regulation O
, O
Improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
Body B-NEU
weight I-NEU

-DOCSTART- O

To O
warm O
the O
kidney B-DNP
and O
cause O
diuresis B-NEG
. O

-DOCSTART- O

Acute B-NEG
Myelogenous I-NEG
Leukemia I-NEG

-DOCSTART- O

Rheumatism B-NEG
numbness I-NEG
, O
damp-heat B-NEG
itchy I-NEG
sore I-NEG
, O
clove B-NEG
sore I-NEG
, O
menstruant O
morbidity O
. O

-DOCSTART- O

Treatment O
of O
cough B-NEG
in O
colds O
with O
retention O
of O
phlegm B-NEG
marked O
by O
dyspnea B-NEG
, O
profuse O
expectoration B-NEG
and O
feeling O
of O
stuffiness B-NEG
in O
the O
chest O
, O
external O
use O
for O
pyogenic B-NEG
infections I-NEG
of O
the O
skin O
. O

-DOCSTART- O

ceruminal B-NEG
impaction I-NEG

-DOCSTART- O

difficult B-NEG
delivery I-NEG
; O

dystocia B-NEG

-DOCSTART- O

Other O
system O
health O
, O
Others O

-DOCSTART- O

Pregnancy B-NEU
Outcome O

-DOCSTART- O

Treatment O
of O
protracted O
diarrhea B-NEG
due O
to O
hypofunction B-NEG
of O
the O
spleen O
, O
seminal B-NEU
emission I-NEU
, O
leukorrhagia B-NEG
, O
palpitation B-NEG
, O
insomnia B-NEG
. O

-DOCSTART- O

To O
remove O
heat O
and O
damp O
, O
to O
counteract O
toxicity B-NEG
, O
and O
to O
cause O
subsidence O
of O
swelling B-NEG
. O

-DOCSTART- O

Symptoms O
associated O
with O
stagnation B-NEG
of I-NEG
liver I-NEG
qi I-NEG
, O
stagnated O
qi O
truned O
into O
fire O
, O
insufficient O
yin O
blood B-DNP

-DOCSTART- O

1 O
Its O
alcoholic O
extract O
exerts O
antipyretic O
and O
analgesic O
effect O
. O

2 O
Its O
aqueous O
extract O
is O
a O
cardiotonic O
. O

-DOCSTART- O

To O
invigorate O
blood B-DNP
and O
remove O
stagnation B-NEG
. O

-DOCSTART- O

Exerting O
prolong O
hypotensive B-NEU
effect I-NEU
in O
anesthetized O
animals. O
. O

-DOCSTART- O

Deficiency O
of O
yin O
of O
the O
liver B-DNP
and O
the O
kidney B-DNP
marked O
by O
tinnitus B-NEG
, O
impairment B-NEG
of I-NEG
hearing I-NEG
, O
dizziness B-NEG
and O
blurred B-NEG
vision I-NEG
. O

-DOCSTART- O

Lung O
cancer O

-DOCSTART- O

Halobetasol O
propionate O
is O
thought O
to O
act O
by O
the O
induction O
of O
phospholipase O
A2 O
inhibitory O
proteins O
, O
collectively O
called O
lipocortins O
. O

It O
is O
postulated O
that O
these O
proteins O
control O
the O
biosynthesis O
of O
potent O
mediators O
of O
inflammation O
such O
as O
prostaglandins O
and O
leukotrienes O
by O
inhibiting O
the O
release O
of O
their O
common O
precursor B-DNP
arachidonic I-DNP
acid I-DNP
. O

Arachidonic O
acid O
is O
released O
from O
membrane O
phospholipids O
by O
phospholipase O
A2 O
. O

The O
initial O
interaction O
, O
however O
, O
is O
due O
to O
the O
drug O
binding O
to O
the O
cytosolic O
glucocorticoid O
receptor O
. O

After O
binding O
the O
receptor O
the O
newly O
formed O
receptor-ligand O
complex O
translocates O
itself O
into O
the O
cell O
nucleus O
, O
where O
it O
binds O
to O
many O
glucocorticoid O
response O
elements O
( O
GRE O
) O
in O
the O
promoter O
region O
of O
the O
target O
genes O
. O

The O
DNA O
bound O
receptor O
then O
interacts O
with O
basic B-DNP
transcription I-DNP
factors I-DNP
, O
causing O
the O
increase O
in O
expression B-NEU
of I-NEU
specific I-NEU
target I-NEU
genes I-NEU
. O

-DOCSTART- O

hemiplegia B-NEG

-DOCSTART- O

Possessing O
broad-spectrum O
antibacterial B-POS
and I-POS
antiprotozoal I-POS
effects I-POS
. O

-DOCSTART- O

restrain O
acid O

-DOCSTART- O

Diet O
related O
cardiovascular B-NEG
disease I-NEG
, O
Overall O
CVD B-NEG

-DOCSTART- O

12-0-tetradecanoyl-phorbol-13-acetate O
isolated O
from O
its O
croton O
oil O
is O
a O
cancerigenic B-NEG
component I-NEG
. O

-DOCSTART- O

Sumatriptan O
is O
a O
serotonin O
agonist O
that O
acts O
selectively O
at O
5HT1 B-DNP
receptors I-DNP
. O

Naproxen O
inhibits O
the O
activity B-DNP
of I-DNP
the I-DNP
enzymes I-DNP
cyclo-oxygenase I-DNP
I I-DNP
and I-DNP
II I-DNP
, O
resulting O
in O
a O
decreased O
formation B-DNP
of I-DNP
precursors I-DNP
of I-DNP
prostaglandins I-DNP
and I-DNP
thromboxanes I-DNP
. O

-DOCSTART- O

affection O
due O
to O
wind-cold B-NEG
; O
common O
cold B-NEG
caused O
by O
wind B-NEG
and O
cold B-NEG

-DOCSTART- O

Treament O
of O
edema B-NEG
or O
retained B-NEU
fluid I-NEU
with O
abdominal B-NEG
distension I-NEG
, O
oliguria B-NEG
and O
constipation B-NEG
, O
amenorrhea B-NEG
due O
to O
blood B-NEG
stasis I-NEG
, O
external O
use O
for O
ringworm B-NEG
and O
verrucous B-NEG
vegetations I-NEG
. O

-DOCSTART- O

To O
eliminate O
phlegm B-NEG
, O
resuscitate O
, O
tranquilize O
, O
suppress O
wind B-NEG
and O
relieve O
convulsion B-NEG
. O

-DOCSTART- O

relieve O
throat B-DNP

-DOCSTART- O

move O
drug O
effect O

-DOCSTART- O

To O
promote O
blood B-DNP
circulation I-DNP
, O
remove O
blood B-NEG
stasis I-NEG
, O
restore O
consciousness B-NEU
, O
remove O
obstruction B-NEG
in O
the O
channels O
, O
suppress O
the O
hyperfunction O
of O
liver-yang O
and O
stop O
endogenous B-NEG
wind I-NEG
to O
relieve O
convulsion B-NEG
. O

-DOCSTART- O

rigidity B-NEG
of O
the O
limbs O
; O

contracture B-NEG
; O

subjective B-NEU
sensation I-NEU
of O
contraction O

-DOCSTART- O

Uncomplicated B-NEG
Falciparum I-NEG
Malaria I-NEG

-DOCSTART- O

Gumiganghwaltang O
( O
GMGHT O
) O
is O
an O
Oriental O
herbal O
prescription O
, O
which O
has O
been O
commonly O
used O
to O
treat O
a O
cold O
and O
inflammatory B-NEG
diseases I-NEG
in O
Korea O
. O

However O
, O
the O
mechanism O
of O
GMGHT O
is O
not O
clear O
. O

In O
this O
study O
, O
we O
investigated O
the O
anti-inflammatory B-POS
mechanism O
of O
GMGHT O
in O
mouse O
peritoneal O
macrophages O
. O

GMGHT O
exerted O
an O
anti-inflammatory B-POS
action O
through O
inhibiting O
lipopolysaccaride O
( O
LPS)-induced O
tumor O
necrosis O
factor O
( O
TNF O
) O
- O
alpha O
and O
interleukin O
( O
IL)-6 O
production O
in O
mouse O
peritoneal O
macrophages O
. O

The O
maximal O
inhibition O
rate O
of O
TNF-alpha O
, O
and O
IL-6 O
production O
by O
GMGHT O
(1 O
mg/ml O
) O
was O
52.31+/-2.8% O
and O
56.31+/-3.1% O
, O
respectively O
. O

In O
the O
inflammatory B-NEG
process I-NEG
, O
cyclooxygenase O
2 O
( O
COX-2 O
) O
and O
inducible O
nitric B-DNP
oxide I-DNP
synthase I-DNP
( O
iNOS B-DNP
) O
increased O
in O
peritoneal O
macrophages O
. O

GMGHT O
decreased O
the O
protein O
level O
of O
COX-2 B-DNP
and O
iNOS B-DNP
in O
LPB-stimulated O
mouse O
peritoneal O
macrophages O
. O

In O
addition O
, O
GMGHT O
inhibited O
nuclear B-NEU
factor-kappaB I-NEU
activation I-NEU
and O
IkappaB-alpha B-DNP
degradation O
. O

Our O
study O
suggests O
that O
an O
important O
molecular O
mechanism O
by O
GMKHT O
reduce O
inflammation B-NEG
, O
which O
might O
explain O
its O
beneficial O
effect O
in O
the O
regulation O
of O
inflammatory B-NEU
reactions I-NEU
. O

-DOCSTART- O

To O
tonify O
the O
spleen B-DNP
, O
to O
relieve O
diarrhea B-NEG
, O
to O
replenish O
the O
kidney B-DNP
, O
to O
arrest O
seminal B-NEU
emission I-NEU
, O
and O
to O
nourish O
the O
heart B-DNP
, O
to O
induce O
tranquillization B-POS
. O

-DOCSTART- O

papule B-NEG

-DOCSTART- O

night B-NEG
sweat I-NEG
; O
night B-NEG
sweating I-NEG
spontaneous B-NEG
sweating I-NEG
during O
asleep O
and O
no O
sweating B-NEU
while O
awake O
, O
chiefly O
caused O
by O
deficiency B-NEG
of O
vital O
essence O
and O
presence O
of O
internal O
heat B-NEU
. O

-DOCSTART- O

Diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
Overall O
CVD B-NEG

-DOCSTART- O

de O
Novo O
Kidney B-DNP
Transplantation O

-DOCSTART- O

bloody B-NEG
stool I-NEG
; O
hematochezia B-NEG

-DOCSTART- O

Anemia B-NEG

-DOCSTART- O

Reproductive B-DNP
systems I-DNP
, O
Mood O
, O
Physical B-DNP
performance I-DNP
and O
fitness B-POS
, O
Menopausal B-NEG
woman I-NEG
, O
Endocrine B-DNP
system I-DNP
, O
Endurance B-NEU
, O
energy O
supply O
and O
recovery O
, O
Mimmuietabolic O
rate/energy O
expenditure O
, O
Metabolism B-NEU
, O
Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
Woman O
, O
Quality O
of O
life O
, O
Neurological B-DNP
systems I-DNP
health I-DNP
, O
Neurological B-DNP
systems I-DNP
, O
Liver B-DNP
, O
Others O
, O
Kids O
, O
Body B-NEU
weight I-NEU
regulation I-NEU
, O
Liver B-DNP
health I-DNP
, O
Strength B-POS
and O
power B-POS
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP
, O
insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
Intelligence B-POS
, O
Overall O
CVD B-NEG
, O
General O
woman O
, O
Body B-NEU
weight I-NEU
, O
Protective B-NEU
immunity I-NEU

-DOCSTART- O

reinforce O
bone B-NEG
fracture I-NEG

-DOCSTART- O

Heat B-NEG
sensation I-NEG
in O
the O
chest O
, O
palms O
and O
soles O

-DOCSTART- O

Juvenile B-NEG
Idiopathic I-NEG
Arthritis I-NEG

-DOCSTART- O

infertility B-NEG

-DOCSTART- O

To O
clear O
heat B-NEU
and O
dry B-NEU
damp I-NEU
, O
check O
dysentery B-NEG
. O

-DOCSTART- O

Purging B-NEG

-DOCSTART- O

Neoplasms B-NEG
, I-NEG
Breast I-NEG

-DOCSTART- O

Anesthesia B-DNP
With O
Use O
of O
LMA O
( O
Laryngeal O
Mask O
Airway O
) O

-DOCSTART- O

pain B-NEG
of O
genitals O
among O
men O
and O
women O

-DOCSTART- O

Ramipril O
is O
an O
angiotensin-converting O
enzyme O
inhibitor O
, O
used O
to O
treat O
high B-NEG
blood I-NEG
pressure I-NEG
and O
congestive B-NEG
heart I-NEG
failure I-NEG
. O

Irbesartan O
, O
by O
blocking O
the O
binding O
of O
angiotensin O
II O
to O
the O
AT1 O
receptor O
, O
promotes O
vasodilation B-NEU
and O
decreases O
the O
effects B-NEU
of I-NEU
aldosterone I-NEU
. O

-DOCSTART- O

Neurological B-DNP
systems I-DNP
, O
Neurological B-DNP
systems I-DNP
health I-DNP
, O
Mental B-NEU
state I-NEU
and I-NEU
performance I-NEU
, O
Neurological B-DNP
systems I-DNP
health I-DNP
, O
Memory B-POS

-DOCSTART- O

a O
symptom B-NEG
of I-NEG
perspiration I-NEG
. O

-DOCSTART- O

support O
five O
viscera B-DNP

-DOCSTART- O

Iohexol O
ia O
used O
in O
myelography O
, O
arthrography O
, O
nephroangiography O
, O
arteriography O
, O
and O
other O
radiographic O
procedures O
. O

-DOCSTART- O

Pseudoephedrine O
relaxes O
bronchial B-DNP
smooth I-DNP
muscle I-DNP
by O
stimulating O
beta2-adrenergic O
receptors O
. O
Hydrocodone O
exerts O
its O
analgesic O
activity O
by O
binding O
to O
the O
mu-receptors O
in O
the O
central B-DNP
nervous I-DNP
system I-DNP
( O
CNS B-DNP
) O
, O
thereby O
mimicking O
the O
effects O
of O
endogenous O
opioids O
. O

-DOCSTART- O

Treatment O
of O
lung B-NEG
abscess I-NEG
with O
purulent B-NEG
expectoration I-NEG
, O
heat B-NEG
in O
the O
lung O
with O
cough B-NEG
and O
dyspnea B-NEG
, O
acute B-NEG
dysentery I-NEG
, O
acute B-NEG
urinary I-NEG
infection I-NEG
, O
carbuncles B-NEG
and O
sores B-NEG
. O

-DOCSTART- O

1 O
For O
cases O
of O
apoplexy O
with O
sudden O
onset O
of O
face B-NEG
distortion,dysphasia,numbness I-NEG
of O
the O
limbs,or O
even O
hemiplegia,rigidty B-NEG
of O
the O
extremities,white O
and O
greasy O
fur O
on O
the O
tongue,floating O
and O
smooth O
pulse,which O
are O
attributive O
to O
attack O
of O
wind-phlegm B-NEG
to O
the O

-DOCSTART- O

affection O
due O
to O
wind-cold B-NEG
; O
common B-NEG
cold I-NEG
caused O
by O
wind B-NEG
and O
cold B-NEG

-DOCSTART- O

insulin B-NEG
sensitivity I-NEG
and O
diabetes B-NEG
risk O
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Woman O
, O
Physical O
performance O
and O
fitness O
, O
Improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
absorption B-NEU
, O
Others O
, O
Body O
weight O
regulation O
, O
General O
woman O
, O
Strength O
and O
power O
, O
Digestion B-POS
, O
Hypersensitivity B-NEG
, O
motility B-POS

-DOCSTART- O

epistaxis B-NEG
; O
nosebleed B-NEG

-DOCSTART- O

diabetics B-NEG
; O
emaciation-thirst B-NEG

-DOCSTART- O

To O
strengthen O
the O
body O
resistance O
to O
consolidate O
the O
constitution O
, O
replenish O
qi O
, O
invigorate O
the O
spleen B-DNP
and O
tonify O
the O
spleen B-DNP
and O
tonify O
the O
kidney B-DNP
to O
relieve O
mental B-NEU
strain I-NEU
. O

-DOCSTART- O

